document incorporate reference portion definitive proxy statement registrant annual meeting shareholder file day conclusion registrant fiscal year end december securities exchange commission pursuant regulation security exchange act amend incorporate reference iii annual report extent describe thereinbristolmyer squibb company index december item business acquisition divestiture license arrangement product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation human capital management resource foreign operation bristol myers squibb website item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ia information executive officer ii item market registrant common equity relate stockholder matter issuer purchase equity security item reserve item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive lossincome consolidated balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item b information item c disclosure foreign jurisdiction prevent inspection iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit index end item business general bristolmyers squibb company company bms incorporate law state delaware august bristol myers company successor new york business start bristolmyer company change bristolmyer squibb company result merger continue operate segment engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis expect acquisition myokardia turning point position lead biopharmaceutical company expand precision oncology cardiovascular portfolio nearterm asset additional external partnership principal strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry focus biopharmaceutical company discover develop deliver transformational medicine patient face disease area believe opportunity meaningful difference oncology hematology immunology cardiovascular neuroscience priority continue renew diversify portfolio launch new product portfolio advance early mid latestage pipeline execute disciplined business development remain committed strengthen balance sheet return capital shareholder discussion strategy initiative refer item management discussion analysis financial condition result operationsstrategy compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency significant manufacturing operation puerto rico ireland switzerland revenue come product follow therapeutic class hematology oncology cardiovascular immunology percentage revenue significant regioncountry follow year end december dollar millions united states international othera total revenue revenue include royalty alliancerelate revenue product sell bmss regional commercial organization refer summary abbreviate term end definition capitalize term document acquisition divestiture license arrangement acquisition divestiture license arrangement allow focus resource growth opportunity drive great longterm value additional information relate acquisition divestiture license arrangement refer item management discussion analysis financial condition result operationsacquisition divestiture license arrangement item financial statement supplementary datanote acquisition divestiture license arrangement product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologics chimeric antigen receptor car tcell therapie small molecule drug typically administer orally form tablet capsule drug delivery mechanism biologic typically administer patient injection intravenous infusion cart therapy administer patient intravenous infusion summary significant product include approve indication information alliance arrangement certain product refer alliance item financial statement supplementary datanote alliance eliquis eliquis apixaban oral factor xa inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy opdivo opdivo nivolumab biological product fully human monoclonal antibody bind pd nkt cell opdivo receive approval anticancer indication include bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc gastric esophageal cancer ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent pomalystimnovid pomalystimnovid pomalidomide small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy orencia orencia abatacept biological product fusion protein indicate adult patient moderately severely active ra psa reduce sign symptom certain pediatric patient moderately severely active polyarticular jia treatment agvhd combination calcineurin inhibitor methotrexate sprycel sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml yervoy yervoy ipilimumab biological product ctla immune checkpoint inhibitor yervoy monoclonal antibody treatment patient unresectable metastatic melanoma empliciti empliciti elotuzumab biological product target slamf protein express natural killer cell nkc myeloma cell empliciti humanize monoclonal antibody treatment multiple myeloma reblozyl reblozyl luspaterceptaamt biological product erythroid maturation agent indicate treatment anemia adult patient transfusion dependent nontransfusion dependent beta thalassemia treatment anemia failing erythropoiesis stimulate agent esa adult patient low intermediaterisk mds ring sideroblast require rbc transfusion abecma abecma idecabtagene vicleucel bcell maturation antigendirecte genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticd monoclonal antibody opdualag opdualag nivolumab relatlimabrmbw combination nivolumab pd block antibody relatlimab lag blocking antibody indicate treatment adult pediatric patient year age old unresectable metastatic melanoma zeposia zeposia ozanimod oral immunomodulatory drug treat moderately severely active uc relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult breyanzi breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory large bcell lymphoma line systemic therapy include diffuse large bcell lymphoma specify highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b onureg onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy inrebic inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary post polycythemia vera postessential thrombocythemia myelofibrosis camzyos camzyos mavacamten cardiac myosin inhibitor indicate treatment adult symptomatic obstructive hcm improve functional capacity symptom sotyktu sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicate treatment adult moderatetosevere plaque psoriasis candidate systemic therapy phototherapy revlimid revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revlimid receive approval indication hematological malignancy include lymphoma mds abraxane abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory data protection rdp exclusivity right develop country provide certain nonpatent incentive development medicine example eu japan certain country rdp exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term eu japan provide rdp period time approval new drug regulatory agency rely innovators data approve competitor generic copy certain market patent protection form market exclusivity expire rdp particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration rdp exclusivity basis competitor safety efficacy datum drug drug identical market innovator patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic medicine business refer competition specific aspect law govern market exclusivity rdp pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application receive certain period regulatory exclusivity nda bla compound designate orphan drug receive seven year exclusivity orphan drug indication period fda generally approve application drug product orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity type application file nda bla affect rdp exclusivity right discuss chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid unenforceable infringe generic product allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph iv certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right medicine approve nda receive type rdp innovative chemical pharmaceutical product entitle year rdp fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear rdp period pharmaceutical drug product contain active ingredient previously approve nda approve example new formulation new route administration drug new indication basis new clinical study receive year rdp formulation route administration indication market chemical product include eliquis pomalyst sprycel zeposia onureg inrebic camzyos sotyktu biologic product include cart cell therapy product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar version file year approval innovator product qualify innovative biological product receive year rdp mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity market biologic product include opdivo orencia yervoy empliciti reblozyl abecma opdualag breyanzi european union patent pharmaceutical product generally enforceable eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product eu centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation ec ec approve deny maa possible new chemical product obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu country process place simultaneously product market eu country process complete company market new product pricing reimbursement procedure month year complete eu product marketing authorization file octobernovember subject rdp regime year innovator receive community authorization medicinal product generic company file maa product health authority maa approved generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment contrast patent eu list regulatory authority generic version pharmaceutical product approve rdp expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general eu law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property rdp addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year rdp approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval rdp patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar eu develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right datum exclusivity currently estimate occur eu japan estimate minimum market exclusivity date sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside eu japan generally estimate minimum market exclusivity date table pertain end rdp composition matter com patent expiration respective product patent term restoration ptr grant situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration rdp estimate minimum market exclusivity date product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limit estimate estimate minimum market exclusivity date euo japan abecma idecabtagene vicleucel abraxane paclitaxela breyanzi lisocabtagene maraleucelb camzyos mavacamtenc eliquis apixaband empliciti elotuzumab inrebic fedratinibe onureg azacitidinef opdivo nivolumab opdualag nivolumab relatlimabrmbwg orencia abatacepth pomalystimnovid pomalidomidei reblozyl luspaterceptaamtj revlimid lenalidomidek sotyktu deucravacitinibl sprycel dasatinibm yervoy ipilimumab zeposia ozanimodn product footnote information currently market product country region indicate abraxane base settlement certain generic permit enter market eu generic enter market japan estimate minimum market exclusivity date base method use patent b breyanzi ptr application pende grant estimate patent expiry c camzyos ptr application pende grant estimate patent expiry eliquis patent list fda orange book composition matter patent claim apixaban specifically expire formulation patent expiring challenge numerous generic company bms partner pfizer settle number generic company settle generic company continue litigate remain generic company remain generic company august district court district delaware decide challenge eliquis patent valid infringe remain generic company remain generic company appeal september court appeal federal circuit uphold decision respect patent term previously execute settlement agreement settle generic company permit date launch settle generic company patent april subject additional challenge eu apixaban composition matter patent relate supplementary protection certificate spc expire generic challenge composition matter patent relate spc jurisdiction trial take place schedule place certain european country legal proceeding pende generic manufacturer begin market generic version eliquis uk netherlands seek market generic version eliquis european country prior expiration date apixaban patent relate spc refer item financial statement supplementary datanote legal proceeding contingency information e inrebic ptr application pende grant estimate patent expiry eu estimate minimum market exclusivity date base rdp exclusivity f onureg estimate minimum market exclusivity date base seven year orphan drug exclusivity formulation patent cover onureg expire eu japan accord healthcare inc challenge formulation patent list fda orange book litigation ongoing eu formulation patent ep ep ep cover onureg pende opposition proceeding epo opposition division find formulation patent invalid decision appeal refer item financial statement supplementary datanote legal proceeding contingency information g opdualag ptr application pende grant estimate patent expiry eu spc application pende grant estimate patent expiry h bms aware orencia biosimilar market eu japan formulation additional patent expire pomalyst currently expect generic entry prior quarter refer item financial statement supplementary datanote legal proceeding contingency information europe estimate minimum market exclusivity date base rdp exclusivity japan estimate minimum market exclusivity date base method use patent j reblozyl europe estimate minimum market exclusivity date base rdp exclusivity ptr application method treatment patent pende grant estimate patent expiry eu spc application method treatment patent pende grant estimate patent expiry k revlimid settlement natco pharma ltd natco partners affiliates natco grant volumelimite license sell generic lenalidomide commence march certain generic company grant volumelimite license sell generic lenalidomide begin confidential date march volumelimite license date provide natco natco certain generic begin market generic lenalidomide product pursuant volumelimite license addition natco generic company grant license sell generic lenalidomide volume limitation begin january eu licenses grant party market generic lenalidomide product prior expiry patent supplementary protection certificate spc right uk begin january major market european country eg france germany italy spain spc force begin february japan composition matter patent expire july bms aware generic approval refer item financial statement supplementary datanote legal proceeding contingency information l sotyktu ptr application pende grant estimate patent expiry japan ptr application pende grant estimate patent expiry sprycel bms enter settlement agreement apotex inc certain generic company patent cover certain polymorphic form dasatinib generic company launch generic dasatinib anda product september early certain circumstance lawsuit file bm pende company file b nda application contain paragraph iv certification seek approval dasatinib product eu epos opposition division uphold validity patent direct use dasatinib treat cml expire settlement agreement certain generic launch generic dasatinib approve indication japan composition matter patent extend treatment nonimatinibresistant cml generics approve indication refer item financial statement supplementary datanote legal proceeding contingency information n zeposia ptr application pende grant estimate patent expiry eu estimate minimum market exclusivity date base rdp exclusivity eu spc application pende grant estimate patent expiry estimate minimum market exclusivity date eu country base france germany italy spain uk research development rd critical longterm competitiveness concentrate rd effort follow disease area significant unmet medical need oncology include lung bladder renal gastric esophageal head neck colorectal melanoma tumor type hematology cell therapy include multiple myeloma lymphoma chronic lymphocytic leukemia immunology include relapse multiple sclerosis psoriasis lupus rheumatoid arthritis inflammatory bowel disease cardiovascular include cardiomyopathy heart failure thrombotic disorder fibrotic disease specifically lung liver continue analyze selectively pursue promising lead area rd pipeline include potential medicine modality include small chemically manufacture molecule large protein moleculesalso know biologicsand degrader tcell nkcell engager millamolecule antibody drug conjugate cellular therapy gene therapy addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation eu foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase ii phase iii clinical study design specifically support application regulatory approval particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase ii clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase ii result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant rd program program include investigational compound phases ii iii development initial indication market product development additional indication formulation substantial component rd program strategy include expand portfolio market product hematology immunology cardiovascular io agent secondline therapy new indication drug development time consume expensive risky rd process ie target identification major market approval typically take fourteen year drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately small molecule enter phase development fail achieve regulatory approval small molecule enter phase ii development failure rate approximately approximately phase iii small molecule fail achieve approval biologic failure rate approximately phase development approximately phase ii development approximately phase iii rd expense include cost discovery research preclinical development earlystage latestage clinical development drug formulation post commercialization medical support market product proportionate allocation enterprisewide cost acquire iprd include upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval rd expense billion billion billion acquire iprd expense million billion billion respectively acquire iprd include billion charge result myokardia acquisition manage rd program product portfolio basis invest resource stage rd early discovery latestage development continually evaluate portfolio rd asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual rd expense opdivo individual investigational compound market product represent rd expense drug discovery development work take place network stateoftheart facility worldwide continue investment exist site expansion manufacturing capability example expand lawrenceville new jersey site open new rd facility cambridge massachusetts plan san diego california plan addition support continue investment cell therapy portfolio expand manufacturing capability construction new stateoftheart cell therapy manufacturing facility deven massachusetts leiden netherlands supplement internal drug discovery development program acquisition alliance collaborative agreement help bring new molecular agent capability platform pipeline broad earlytomid stage pipeline unique asset clinical development pipeline build couple internal research development program distribute research development model focus identify support development disruptive innovative therapy outside company broad network external partnership management continue emphasize leadership innovation productivity quality strategy success rd activity list clinical study approve indication market product relate therapeutic area february list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound hematology phase phase ii phase iii approve indication additional indication additional indication additional indication abecma opdivo abecma abecma l relapsedrefractory multiple myeloma hematologic malignancies l multiple myeloma l multiple myeloma l relapsedrefractory multiple myeloma breyanzi inrebic breyanzi l chronic lymphocytic leukemia mf previously treat l large bcell lymphoma investigational compound l follicular lymphoma ruxolitinib l large bcell lymphoma alnuctamab bcma tce l marginal zone lymphoma reblozyl empliciti pomalystimnovid mre yla ep los me arefractory multiple l mantle cell lymphoma l td mds associate anemia relapsedrefractory multiple myeloma antisirp onureg l td mf associate anemia empliciti revlimid hematologic malignancy lowtointermediate risk mds relapsedrefractory multiple myeloma bcma adc opdivo empliciti investigational compound idhifa relapsedrefractory multiple relapsedrefractory multiple iberdomide relapsedrefractory acute myeloid leukemia myeloma myeloma l multiple myeloma inrebic bcma nke reblozyl mezigdomide cc myelofibrosis relapsedrefractory multiple athalassemia subq l multiple myeloma onureg myeloma idhifa postinduction acute myeloid leukemia bet inhibitor cc l acute myeloid leukemia maintenance hematologic malignancy opdivo cd nke advanced hodgkin lymphoma investigational compound relapsedrefractory multiple pomalystimnovid myeloma ai celmod cc multiple myeloma cdxcd lr ye mlap ps od mr aefractory nonhodgkin relapsedrefractory multiple myeloma nonhodgkin lymphoma bet inhibitor bms aid relate kaposi sarcoma ck degrader hematologic malignancy hivnegative kaposi sarcoma hematologic malignancy iberdomide reblozyl gprcd cart newlydiagnose multiple transfusiondependent betathalassemia relapsedrefractory multiple myeloma mds previously treat esa myeloma revlimid gspt celmod cc l multiple myeloma relapsedrefractory acute myeloid leukemia mantle cell lymphoma iberdomide mds l diffuse large bcell lymphoma multiple myeloma l follicular lymphoma previously treat follicular lymphoma relapsedrefractory nonhodgkin relapsedrefractory adult tcell lymphoma leukemialymphoma large bcell lymphoma sprycel l cml pediatric refractory cml oncology phase phase ii phase iii approve indication additional indication additional indication additional indication abraxane opdivo opdivo opdivo breast solid tumor solid tumor periadjuvant muscle invasive gastric opdivo yervoy l crc urothelial carcinoma locally advanced metastatic nsclc solid tumor pan tumor tmb high adjuvant gastric cancer metastatic breast cancer opdivo yervoy adjuvant hcc nsclc solid tumor adjuvant melanoma pancreatic l metastatic castration l metastatic castration unresectable pancreatic investigational compound resistant prostate cancer resistant prostate cancer opdivo ahr antagonist opdivo cdk inhibitor ip iie ari aad dju juv va not n ns sc cl lc c tage ib l metastatic melanoma solid tumor neoadjuvant erher breast opdivo yervoy l gastric anticcr nivolumab relatlimab l bladder cancer esophageal squamous cell carcinoma solid tumor l stage iv nsclc l hcc l esophageal antiilt hepatocellular carcinoma l msihigh crc h adjuvant melanoma solid tumor adjuvant rcc adjuvant bladder arldd stage iii unresectable nsclc adjuvant esophagealgastroesophageal solid tumor opdualag fix dose mesothelioma antinkga investigational compound nivolumab relatlimab previously treat advanced rcc antictla nf probody adjuvant melanoma previously treat gastric cancer japan china solid tumor therapeutic l microsatellite stable previously treat metastatic head neck claudin adc solid tumor metastatic crc previously treat metastatic melanoma advance solid tumor antifucosyl gm l melanoma subq previously treat metastatic msihigh crc cdxpsca bispecific solid tumor previously treat metastatic nonsquamous nsclc solid tumor previously treat metastatic squamous nsclc antiil dgk inhibitor previously treat metastatic urothelial cancer solid tumor solid tumor investigational compound previously treat esophageal cancer jnk inhibitor antitigit subcutaneous nivolumab neoadjuvant nsclc solid tumor rhuph solid tumor opdivo cabozantinib l rcc bet inhibitor cc metastatic rcc lsd inhibitor adjuvant melanoma solid tumor opdivo yervoy solid tumor farletuzumabecteribulin l metastatic melanoma mage tcer solid tumor l mesothelioma solid tumor l nsclc repotrectinib shp inhibitor l rcc ros nsclc solid tumor previously treat metastatic msihigh crc ntrk pan tumor tgf inhibitor previously treat hcc solid tumor l esophageal l gastric tigit bispecific opdualag fix dose nivolumab relatlimab solid tumor l melanoma yervoy adjuvant melanoma metastatic melanoma immunology phase phase ii phase iii approve indication investigational compound additional indication additional indication orencia afimetoran tlr inhibitor sotyktu deucravacitinib sotyktu deucravacitinib active polyarticular jia cutaneous lupus erythematosus crohn disease psoriatic arthritis early rheumatoid arthritis anticd alopecia areata systemic lupus erythematosus jia intravenous autoimmune disease ulcerative colitis zeposia jia subcutaneous ripk inhibitor discoid lupus erythematosus crohns disease psoriatic arthritis autoimmune disease ra auto injector ilcd ra intravenous autoimmune disease ra subcutaneous pkc inhibitor investigational compound investigational compound acute graft versus host disease autoimmune disease afimetoran cendakimab sotyktu deucravacitinib tyk inhibitor systemic lupus erythematosus eosinophilic esophagitis moderatetosevere psoriasis autoimmune disease zeposia relapse multiple sclerosis moderatetosevere ulcerative colitis cardiovascular phase phase ii phase iii approve indication investigational compound additional indication additional indication camzyos mavacamten factor xia inhibitor camzyos mavacamten camzyos mavacamten symptomatic obstructive hypertrophic thrombotic disorder heart failure preserve nonobstructive hypertrophic cardiomyopathy ejection fraction hfpef cardiomyopathy eliquis milvexian stroke prevention atrial fibrillation secondary stroke prevention ssp venous thromboembolism prevention orthopedic surgery investigational compound venous thromboembolism treatment cardiac myosin inhibitor myk obstructive hypertrophic cardiomyopathy danicamtiv genetic dilate cardiomyopathy fibrotic disease phase ii investigational compound hsp nonalcoholic steatohepatitis lpa antagonist pulmonary fibrosis neuroscience phase investigational compound antitau neuroscience btk inhibitor neuroscience eifb activator neuroscience faahmgll dual inhibitor neuroscience note pipeline exclude clinical collaboration development partnership abecma idecel seventy bio ahr ikena oncology antitau prothena camzyos china singapore thailand macau hk taiwan lianbio claudin adc lanova medicine cdxpsca avencell eifb activator evotec eliquis pfizer empliciti abbvie farletuzumab ecteribulin eisai hsp nitto denko corporation rhuph halozyme idhifa servi magea tcer immatic milvexian janssen pharmaceuticals inc opdivo yervoy opdualag ono reblozyl merck shp inhibitor bridgebio pharma tigit bispecific agenus pkc inhibitor exscientia trial explore combination partnerrun study follow registrational study readout anticipate oncology hematology asset tumor trial time asset disease trial time opdivo yervoy l hcc cmdw l cll transcendcll breyanzi opdivo yervoy l msi high crc cmhw l follicular lymphoma transcendfl opdivo yervoy adj hcc cmdx reblozyl l myelofibrosis independence stage iii unresectable opdivo yervoy cml nsclc opdivo periadjuvant mibc cm immunology opdivo l mcrpc cmdx asset disease trial time moderate severe crohns opdivo periadjuvant nsclc cmt zeposia yellowstone disease stage ibiiia adjuvant opdivo anvil sotyktu psa m nsclc opdualag l mss mcrpc relativity cendakimab eoe imp partner run study alliance enter alliance arrangement party development commercialization specific product drug candidate therapeutic area focus alliance structure codevelopment cocommercialization license joint venture arrangement arrangement include upfront payment option payment develop commercialize specific asset technology payment developmental regulatory salesbase performance milestone royalty cost reimbursement profit sharing equity investment provision alliance arrangement lessen investment risk compound lead revenue generating product reduce profitability market product profit share royalty payment actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern arrangement typically provide termination bms cause notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure bms terminate cause bms right terminate cause exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation loss cash flow cause loss right material financial condition liquidity alliance agreement structure terminate specific date product patent expiration date expiry date profit sharing payment typically expiration date royalty payment typically cease loss market exclusivity include patent expiration refer item financial statement supplementary datanote alliance information significant alliance agreement alliance agreement marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor specialty pharmacy less extent directly distributor retailer hospital clinic government agency revlimid pomalyst distribute united states primarily contract pharmacy lenalidomide risk evaluation mitigation strategy rem revlimid pomalyst rem program respectively proprietary mandatory riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use camzyos available restrict program call camzyos rem program product distribution limit rem certify pharmacy enrol pharmacy dispense patient authorize receive camzyos program vary country depend country design riskmanagement program product sell hospital retail pharmacy refer item financial statement supplementary datanote revenue gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire june subject certain termination provision nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion competition market compete generally broadbase highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service rd new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer io therapy continue evolve rapid pace io product particularly opdivo operate highly competitive marketplace addition compete market share io product approve indication lung cancer melanoma face increase competition exist compete io product receive fda approval additional indication new io agent receive fda approval enter market furthermore therapy combine different io product io product exist chemotherapy target therapy treatment investigate potential expand approval anticipate io product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer certain country include eu regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far rd researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number eu country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribed key primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent challenge generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing patient support program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize collaboration appropriate improve access care supportive service vulnerable patient collaboration demonstration project important factor pricing medicine depend government regulation subject increase international domestic effort government implement strengthen measure regulate pharmaceutical market access product pricing payment require provide discount purchase pharmaceutical product federal state healthcare program federal government official legislator continue face intense pressure public manage perceive high cost pharmaceutical respond pursue legislation recently enact inflation reduction act ira rules claim potentially reduce cost drug federal government stakeholder require comply recently enact state law seek additional transparency cost prescription drug monitor effort state seek additional rebate limit state spend drug light budget pressure international federal state legislative regulatory development create new constraint ability set price andor impact market access certain area discussion pricing pressure risk refer item businessgovernment regulation item risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin growth consolidation mcos pbm optum uhc cvs health cvs express script esi major factor healthcare marketplace mcos pbms consolidate few large entity enhance purchasing strength importance half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physicians physician organization pbms party support formulary management contracting mco successfully compete formulary position mcos pbms demonstrate product offer medical benefit cost advantage compare form care exclusion product formulary lead sharply reduce usage patient population consequently pharmaceutical company compete aggressively product include new product introduce compete product market product later develop competitor possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy usually provide rebate pbm important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco pbm formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject direct government control point care government significant power primary payer result product face restrict access pricing pressure public private payer subject assessment comparative value effectiveness exist standard care government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut rebate scheme method cost control eu countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing price reevaluate restrict life medicine eu markets germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product year elapse new medicine available patient market additionally country outside regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spending clawback free product portion expect therapy period trend accelerate recent year example germany reform pricing reimbursement system restrain pharmaceutical spending reduce free pricing period introduce new costcontainment measure medicine base value assessment result use combination medicine japanese government continue impose price cut outside normal repricing cycle year introduce new value assessment requirement medicine cut price existence price differential market particularly neighboring country different national pricing reimbursement condition lead potential parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency rebate drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market regulatory review process resource intensive undertake fda pharmaceutical company improvement efficiency process significant impact bring new therapy patient quickly fda employ tool facilitate development certain drug expedite certain application include fast track designation breakthrough therapy designation priority review accelerate approval incentive orphan drug develop rare disease example recent year fda oncology center excellence oce establish project test novel approach efficient regulatory review oncology drug realtime oncology review pilot program assessment aid assessment aid pilot program fda approve opdivoyervoy give cycle platinumdoublet chemotherapy firstline treatment adult patient metastatic recurrent nsclc egfr anaplastic lymphoma kinase genomic tumor aberration approval achieve month priority review pdufa date august develop framework concurrent review supplemental oncology application multiple approval authority oce initiate project orbis project orbi early approval australian therapeutic good administration tga health canada singapore health sciences authority receive combination opdivoyervoy give cycle platinumdoublet chemotherapy fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse event use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug ii impose certain safety relate drug labeling change iii mandate risk mitigation measure education healthcare provider restrict distribution medicine iv require company publicly disclose datum clinical study v prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize knowingly offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement administration procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate medicaid drug rebate program mdrp pay rebate state medicaid program cover outpatient drug provide medicaid beneficiary rebate base pricing datum report regularly center medicare medicaid services cms participate public health services b program charge statutorily define covered entity b program ceiling price cover outpatient drug price calculate base mdrp report datum participate federal government program specify discount certain federal government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase august president biden sign ira provide government set negotiate price select highcost medicare begin medicare b drug begin year smallmolecule drug year biological product fda approval ii manufacturer pay rebate medicare b drug price increase fast inflation begin medicare medicare b drug iii medicare redesign replace current coverage gap provision establish cap outofpocket limit cost medicare beneficiary begin manufacturer responsible cost cap cap reach implementation ira expect carry upcoming action regulatory authority outcome uncertain discussion legislation impact refer item management discussion analysis financial condition result operationsexecutive summary activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda ec approval obtain product approval product comparable regulatory authority country outside eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material component supply require manufacturing product open market product purchase raw material component supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate potential risk associate raw material component supply inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network consist internal external resource manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical manufacturing process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval manage operate flexible manufacturing network minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation significant biologic cell therapy pharmaceutical manufacturing facility locate puerto rico ireland switzerland require significant ongoing capital investment maintenance compliance increase regulatory requirement example fda approve large scale multi product bulk biologic manufacturing facility deven massachusetts continue capital investment facility addition expect continue modification exist manufacturing network meet complex processing standard require grow portfolio particularly biologic cell therapy biologic manufacturing involve complex process traditional pharmaceutical operation example complete new largescale biologic manufacturing facility cruiserath ireland approve fda december eu january cell therapy product candidate market product include breyanzi abecma invest manufacturing network include facility bothell washington summit new jersey deven massachusetts leiden netherlands thirdparty manufacturer regulatory requirement product involve technically sophisticated manufacturing process require specialized raw material example manufacture clinical commercial use sterile product biologic product cart product particularly complex involve highly specialized manufacturing technology result slight deviation point production process lead production failure recall order address production constraint cart cell therapy manufacturing continue partner party manufacturer expand supply vector invest new facility drug product manufacturing longerterm accelerate plan transition new vector technology dual source strategy addition manufacture site rely party manufacture supply portion active product ingredient drug substance necessary manufacture product include opdivo eliquis sprycel yervoy reblozyl inrebic abraxane pomalystimnovid expand use thirdparty manufacturer drug product finish good manufacturing continue shift thirdparty manufacturer supply mature brand maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier reduce risk interruption manufacturing operation certain supply arrangement extend multiple year commit amount expect near longterm demand requirement subject change additional protection case step maintain approve backup source available need example capability manufacture opdivo drug product internally arrangement thirdparty manufacturer meet demand opdivo drug substance drug product connection acquisition divestiture license collaboration arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party intend continue enter arrangement agreement future addition liability arise failure supply product agreement arrangement agreement require invest facility manufacture nonstrategic product case divestiture distribution arrangement result additional regulatory filing obligation cause interruption manufacture strategic product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility maintenance planning manufacturing warehouse logistic distribution maintain record demonstrate quality integrity datum technical information production process control production process involves establish specification standard raw material component ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process raw material drug substance final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier help ensure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment occupational health safety sustainability group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statement supplementary datanote legal proceeding contingency human capital management resource believe employee world embody mission discover develop deliver innovative medicine help patient prevail disease unyielde focus patient define culture demographic december approximately employee country approximately employee locate exclude puerto rico locate outside supplement employee population independent contractor contingent worker temporary workforce support need average tenure employee approximately seven year people strategy bms global community compassionate purposedriven professional live vision transform patient live science people strategy design foster inclusive engage work experience attract develop retain talented workforce reflect diverse culture background experience patient community world strive inspire career experience enable people realize aspiration nurture healthy energize flexible workplace foster collaboration innovation cultivate inclusive environment diverse workforce feel sense belong value unique perspective excel pursuit science innovation patient prioritize investment enterprisewide comprehensive cohesive strategy program policy initiative describe accelerate personal development collaboration service patient believe investment competitive advantage recruit develop retain future workforce drive innovation people practice unrelenting push breakthrough science global inclusion diversity inclusion diversity d strengthen foundation bms achieve breakthrough help serve unmet evolve need patient community world compel longstanding commitment elevate inclusion diversity health equity drive equitable advancement outcomes global inclusion diversity strategy lead value inclusion core value regionally locally relevant strengthen human connection bring work day discover develop deliver medicine help patient prevail disease thrive culture belong cultivate encourage inclusive engagement innovation encourage employee world diverse culture background experiencesto authentic self work speak think boldly create energized environment cocollaboration codesign bold idea solution lead improved patient outcome patient community colleague industry deserve global d strategy enable people business resource group operationalize organization design ongoing investment people business resource group pbrg represent key lever use enable global inclusion diversity strategy maintain pbrg chapter worldwide member network learn skill participate learn development event contribute global inclusion diversity strategy tangible way pbrg sponsor member leadership team lead fulltime dedicated leader report directly member leadership team pbrg include black organization leadership development bms network woman cultivate leadership innovation millennial disability advancement workplace network pride alliance organization latino achievement pan asian network veteran community network pbrg membership grow unique member chapter country december approximately bms employee member pbrg remain committed achieve d health equity goal set include address health disparity increase clinical trial diversity enhance supplier diversity program invest puerto rico employee give program increase workforce diversity executive level make meaningful progress goal continue advance d strategy drive equitable access outcome patient communitie globally career growth development bms enterprise learn vision build workforce capable accelerate future growth power mindset continuous learn bms champion learn development people important asset recognize potential achieve career aspiration drive business success aspire create future ready workforce develop critical skill need tackle organization press strategic priority ondemand openenrollment learning journey customize nominationbase experience aim unlock personal potential exceptional learning experience extensive library resource available multiple language employee cover wide range specialized subject employee enrol professional manager leadership development program tuition reimbursement offer globally eligible employee initiation desire development participate accredit highereducational program support pbrg affiliation tour duty stretch assignment opportunity challenge people encourage ownership skill development career advancement employee engagement routinely conduct confidential employee engagement survey global workforce provide feedback employee satisfaction engagement cover variety topic company culture value execution strategy diversity inclusion individual development survey result review executive officer board director analyze area progress opportunity company level function level individual manager use survey result implement action activity intend increase wellbee employee believe employee engagement initiative competitive pay benefit program career growth development opportunity help increase employee satisfaction tenure reduce voluntary turnover give criticality engage motivated workforce select employee engagement goal incorporate annual bonus program metric executive employee health commit protect workforce community patient ensure continue supply lifesave medicine focus direct ensure employee temporary contractor visitor site work safely prioritize health safety employee covid pandemic continue supply medicine patient drive strong business performance sciencebase company social responsibility help reduce spread pandemic vaccination require generally employee puerto rico subject local regulation limit restrict vaccine mandate recognize important role vaccination play reduce impact covid overwhelming majority global workforce vaccinate request medical religious accommodation consider individual basis reward wellbee provide highly competitive benefit compensation work life offering reflect reward wellbee strategy enable workforce deliver business strategy transform patient live science reward program include competitive base salary annual bonus program salesbase incentive special allowance longterm incentive peertopeer individual recognition respect executive substantial proportion pay variable atrisk base financial operational result deliver form equity support alignment executive compensation plan creation longterm value shareholder benefit plan program necessarily vary country include choice health coverage include medical pharmacy dental vision pretax saving spending account financial protection life insurance supplemental health insurance personal coverage protection financial saving highly competitive k saving plan financial wellbeing service promote wellbee workforce develop live life well strategy include program globe support physical emotional financial wellbeing live life well strategy cornerstone people total reward strategie health workforce critical ensuring meet important mission help patient signature program include onsite fitness center support gym membership global employee assistance program provide support time crisis hardship mental health peertopeer ally network financial management seminar tool generous tuition reimbursement program work life offering provide support welcome nurture family member pay parental leave care new child bridge parent leave ease transition new parent work adoptionsurrogacy reimbursement fertilityinfertility benefit support travel mother pay family care leave assist employee manage life workday child elder pet care resource commuter account pay sick time provide employee opportunity recharge community vacation holiday annual pay volunteer day pay bereavement leave pay military leave pay military family care leave addition offer market competitivebase salary overall total reward package annual incentive recognize reward company performance individual result longterm equity incentive spur employee focus longterm value creation foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristol myers squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec pursuant section securities exchange act amended exchange act document available secs website wwwsecgov information relate corporate governance bristol myers squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director board include board committee committee charter transaction bristol myers squibb security director executive officer available website usour company leadership investor caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsshareholder service caption addition information sustainability program available website ussustainability caption forego information website content convenience information contain connected website deem incorporate reference file sec incorporate reference certain information part definitive proxy statement annual meeting shareholder proxy statement sec allow disclose important information refer manner refer information proxy statement available website investorsfinancial reportingsec filing caption day end fiscal year item risk factor risk uncertainty describe significantly negatively affect business operation financial condition operate result include component financial result cash flow prospect reputation credit rating future cause trading price common stock decline significantly additional risk uncertainty presently know risk currently consider immaterial impair business operation financial condition operate result cash flow follow discussion risk factor contain forwardlooke statement discuss item management discussion analysis financial condition result operationsspecial note forwardlooke statement product industry operational risk increase pricing pressure restriction abroad continue negatively affect revenue profit margin product continue subject increase pressure portfolio pharmaceutical market access pricing control require rebate discount eu region world result low price low reimbursement rate small population payer reimburse expect market access constraint pricing control discount restriction acute public private payer continue aggressive step control expenditure future revenue profit margin negatively affect include result change law regulation relate pricing reimbursement pharmaceutical product include potential penalty increase price rate inflation new discount fund redesign medicare benefit government negotiationsprice control establish maximum allow pricereimbursement rate change relate federal healthcare program modify federal anti kickback statute discount safe harbor ira include number provision intend low cost drug cover medicare medicare b limit medicare beneficiary outofpocket spending medicare benefit ii costcutte measure federal healthcare program medicare medicaid mcos institutional governmental purchaser iii grant additional authority governmental agency manage drug utilization negotiate drug price include implementation regulation issue federal government authorize state private party develop implement program import certain prescription drug canada sell american rescue plan act eliminate medicaid prescription drug rebate cap start january iv expand utilization b drug pricing program b program v competition relate placement applicable commercial medicare formularie vi change federal pharmaceutical coverage reimbursement policy practice vii increase scrutiny drug manufacturer include additional review bms celgene house oversight reform committee viii reimbursement delay ix government price erosion mechanism europe country result deflation pharmaceutical product pricing x increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary xi collection delay failure pay governmentfunde public hospital outside xii development technology andor industry practice impact reimbursement policy practice thirdparty payer xiii inhibit market access real perceive difference value proposition product compare compete product additionally manufacturer find knowingly intentionally overcharge b program cover entity subject significant monetary penalty course past year celgene receive inquiry human resource services administration limited distribution network revlimid pomalyst thalomid compliance b program broad integration strategy alignment distribution model post acquisition celgene corporation announce beginning march recognize designate b program contract pharmacy location b program hospital lack entityowne pharmacy believe comply continue comply applicable legal requirement additional legal legislative change respect b program cause update approach significant change sale pricing practice regard distribution drug b program material change payer channel mix adverse effect revenue profitability addition require pay penalty applicable regulation adverse effect revenue profitability additional information pricing pressure constraint refer item businesspricing price constraint market access experience difficulty delay development commercialization new product ability replace revenue product lose patent protection directly dependent ability successfully commercialize new product timely manner common pharmaceutical industry bms expect sale key brand product like revlimid pomalyst sprycel abraxane decline loss market exclusivity product consequently future success highly dependent pipeline new product high rate failure inherent research development process new drug result high risk fund invest research program generate financial return compound product appear promise development fail reach market expect optimal timeframe experience setback continue addition product extension additional indication approve furthermore product indication approve fdas accelerate approval program contingent verification description clinical benefit confirmatory study study successful develop commercialize new compound product involve inherent risk uncertainty include efficacy safety concern finding superior safety efficacy compete product ii delay deny regulatory approval include result difficulty enrol patient complete clinical trial timely manner iii delay challenge produce product commercial scale excessive cost manufacture product iv failure enter implement optimal alliance development andor commercialization new product v change regulatory approval process policy cause delay denial new product approval vi preclusion commercialization intellectual property issue dispute party vii failure certain market obtain reimbursement commensurate level innovation clinical benefit present product viii change clinical preference change industry standard law regulation competitor innovation render new product enhancement exist product obsolete unable predict change law regulatory policy occur affect business particularly pipeline new product regulatory approval delay especially common product expect risk evaluation mitigation strategy rem program require fda address significant riskbenefit issue expect certain future key product distribute primarily rem program inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle provide assurance product development approve launch product launch commercially successful public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key latestage product candidate delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure shortterm longterm material adverse effect business result operation cash flow financial condition prospect assurance key product candidate prove safe effective safe effective compete product approve product commercially successful approve indication lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain maintain patent intellectual property right limitation use loss right result rapid loss sale affect product material country include certain eu member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty addition manufacturer innovative drug generic drug manufacturer able design product own license patent compete result alternative technology absent relevant patent protection product datum exclusivity period expire generic alternative version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject validity enforceability infringement challenge patent litigation postgrant review patent office proceeding confident strength intellectual property right possible generic drug company successfully challenge right launch generic version drug prior expiration intellectual property right example follow certain adverse judicial decision uk netherland generic manufacturer begin market generic version eliquis uk netherlands seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe addition order avoid uncertainty expense litigation reason decide enter settlement generic manufacturer permit generic market entry prior expiration intellectual property right example result patent settlement generic entry revlimid united kingdom begin january european country february similarly follow patent settlement certain company grant volumelimite license sell generic lenalidomide commence march case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation addition country allow manufacturer manufacture sell generic product negatively impact protection afford company lowerprice generic biosimilar bms biologic product compete biologic negatively impact volume price addition congress fda take step promote development approval generic drug biosimilar biologic include provide generic biosimilar developer private right action obtain sufficient quantity drug sample reference product manufacturer order conduct testing necessary obtain approval generic biosimilar product assurance particular product enjoy market exclusivity time period appear estimate disclose form k assume provide financial guidance face intense competition manufacturer expect increase market penetration lowerprice generic product future growth bms dependent market access uptake expansion market brand new product introduction new indication product extension copromotional activity alliance partner competition keen lose exclusivity market brand lowerpriced generic product increasingly penetrate market generic challenge product arise time patent prevent emergence generic competition product country patent protection significantly weak united states eu political social pressure push legislation measure promote use generic biosimilar product additional information item risk factorswe lose market exclusivity product early expect addition face competition new product enter market particularly io new product lower price ii superior efficacy benefit safety risk profile actual perceive iii technological advantage product convenient use iv well insurance coverage reimbursement level v effective marketing program andor differentiate factor hard product compete predict accuracy timing impact introduction competitive product treat disease condition like treat product product candidate business combination competitor major thirdparty payer increase competition product unable compete successfully competitor product marketplace material negative impact revenue earning experience difficulty delay disruption supply chain manufacture distribution sale product product supply relate patient access future negatively impact difficulty delay disruption manufacture distribution sale product difficulty delay disruption include product seizure recall force closing manufacture plant ii failure failure vendor supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay iv failure supplier include sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality v failure thirdparty manufacturer supply bulk active finished product time vi construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption ix disruption supply chain continuity include market force recent stress global logistic natural disaster global disease outbreak pandemic include covid act war terrorism unforeseeable unavoidable event materially impact facility critical supplier addition manufacturing process novel cellbase therapy cart cell therapy evolve process complicate expensive approach take current future competitor ability source raw material supply manufacture cart cell therapy develop consistent reliable manufacturing process distribution network attractive cost good impact future anticipate revenue gross profit cart cell therapy furthermore face challenge source raw material supply clinical approve commercial manufacture logistical shipment delay factor control prevent delay delivery product candidate market product patient additionally require maintain complex chain identity custody respect patient material material enter move manufacturing process result slight deviation point production process cart cell therapy material cart cell therapy result loss product regulatory remedial action adversely affect future anticipate revenue andor profitability relate cart cell therapy regulatory intellectual property litigation tax legal compliance risk litigation claim infringement intellectual property adversely affect future revenue operate earning certain subsidiary future involve legal proceeding include patent litigation claim patent invalid unenforceable andor cover product generic drug manufacturer party seek damage andor injunctive relief compensate allege infringement patent commercial activity resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage andor injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute ii adverse decision litigation include product safety liability consumer protection commercial case iii anti bribery regulation foreign corrupt practice act uk bribery act include compliance ongoe reporting obligation government result settlement iv recall withdrawal pharmaceutical product force closing manufacture plant v allege failure fulfill obligation supply contract government customer agreement relate business vi product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law regulation viii environmental health safety sustainability matter include regulatory action response climate change ix tax liability result assessment tax authority subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company law regulation control regulate key aspect business include limited market access pricing control discount ii tax liability return payment iii import trade restriction iv intellectual property protection enforcement v good practice guideline regulation vi accounting standard vii datum storage privacy particularly eu viii requirement report payment value transfer healthcare professional provide federal antikickback statute ix compliance antibribery anticorruption practice country addition healthcare industry highly regulate subject frequent substantial change including result new judicial governmental decision example fda indicate undertake industrywide review indication receive accelerate approval confirmatory study meet primary endpoint anticipate continue congressional interest modify provision patient protection affordable care act aca particularly give numerous legal challenge california v texas case polarize public support revenue generate health insurance exchange medicaid expansion aca material impact change law similar recent administration action expect limited future replacement modification repeal aca adversely affect business financial result particularly legislation reduce incentive employersponsored insurance coverage predict future federal state legislative administrative change relate healthcare reform affect business additional information refer item businessgovernment regulation item businesspricing price constraint market access change tax regulation negatively impact earning subject income taxis country globally change tax law regulation occur example tax cut job act tcja reduce tax rate introduce broad complex change result numerous new regulation interpretation significant judgment require determine company tax liability company tax return periodically examine tax authority face continue face audit challenge apply tax law regulation ultimate resolution tax matter result payment great amount accrue negative impact provision income taxis addition future earning negatively impact change tax legislation include change tax rate tax base limit phasingout eliminate deduction tax credit increase tax certain excess income intellectual property revise tax law interpretation domestic foreign jurisdiction change rule earning repatriation change tax law country notably july october oecdg inclusive framework agree general rule redefine jurisdictional taxation right global minimum tax december eu member state voted unanimously adopt directive implement pillar global minimum tax rule give member state december implement directive national legislation detail implementation rule expect implement material impact tax provision result operation failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing human resource finance datum business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization ii produce reliable result iii perform timely manner iv maintain confidentiality proprietary information v incur significant cyberattack business disruption vi subject government order mandate require priority government set aside preexist commercial order vii dispute arise respect ownership right technology develop partner viii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party satisfactorily meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act uk bribery act eus general data protection regulation similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence product labeling change market product result negative impact revenue profit margin pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration additional clinical trial headto head study adverse event report follow use product long period time study identify biomarker objective characteristic indicate particular response product therapy conduct obtain marketing approval product regulatory change standard safety efficacy labeling result product label change measure reduce product market acceptance result decline revenue additional information new study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution mcos scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact operating result new information add product label affect risk benefit profile lead potential voluntary mandatory recall withdrawal decline revenue product liability claim additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue addition safety efficacy concern raise party product class product concern implicate entire class turn adverse impact availability commercial viability product product class illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug product divert authorized market risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand divert product prevalence counterfeit medicine industrywide issue variety factor include adoption ecommerce increase covid pandemic greatly enhance consumer ability obtain prescription medical treatment internet lieu traditional brick mortar pharmacy internet expose patient great risk prefer vehicle dangerous counterfeit offer scam anonymity afford counterfeiter theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use social medium cause brand damage information leakage rise liability include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill cause significant volatility stock price disclosure nonpublic companysensitive information workforce intentional unintentional external medium channel lead loss trade secret intellectual property company commercially sensitive information information technology cybersecurity risk dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively information technology system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor party vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction modification confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider covid pandemic progress observe increase cybersecurity incident industry predominantly ransomware social engineering attack government entity subject cyberattack cyberthreat landscape evolve attack grow frequency sophistication intensity nature attack risk remain undetected period time aggregate impact cybersecurity breach datum leakage operation financial condition material date target cyberattack expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat maintain cyber insurance insurance sufficient cover financial legal business reputational loss result interruption breach system assurance continue effort prevent breakdown breach thirdparty provider database system adversely affect business strategic business development employee attraction retention risk depend key product revenue cash flow earning derive majority revenue earning key product expect revlimid eliquis opdivo represent significant percentage revenue earning cash flow year reduction revenue product loss market exclusivity factor adversely impact earning cash flow additional information item risk factorswe lose market exclusivity product early expect major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity supply disruption manufacturing operation party supplier significant advancement compete product incur adverse impact business financial condition result operation trading price stock thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture diabete business include transfer certain future royalty right pertain amylin onglyza farxiga product sale outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion pretax income adversely affect royalty stream decline future period failure execute business strategy identify effectively manage acquisition divestiture alliance joint venture portfolio action adversely impact growth profitability future result addition business asset acquire future underperform able successfully integrate exist business occurrence number unexpected factor prevent substantially delay consummation anticipate acquisition divestiture merger strategy focus deliver innovative transformational medicine patient focus set disease area support future revenue growth maintain adequate pipeline acquire inlicense number asset expect continue support pipeline compound product obtain licensing acquisition competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable consistently maintain adequate pipeline internal rd program transaction party unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact additionally future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy result cost saving avoidance increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include rd manufacturing distribution sale marketing promotion information technology activity ii policy procedure process control compliance iii tax consideration acquire debt equity security consideration business development activity connection joint venture acquisition value security fluctuate depreciate value control company acquire security connection collaborative arrangement result limited ability determine management operational decision internal control compliance policy result additional financial reputational risk successful separate underperform nonstrategic asset gain loss divestiture lose operating income asset affect earning divestiture result continued financial exposure divest business guarantee financial arrangement continue supply service arrangement potential litigation follow transaction arrangement nonperformance result obligation impose material adverse effect competitive position cash flow result operation financial condition reputation incur asset impairment charge related acquisition divestiture reduce earning value allocate certain asset substantially impair number factor control new revise accounting standard rule interpretation result change recognition income expense materially adversely affect financial result execution implementation acquisition divestiture alliance joint venture portfolio action successful adversely impact financial condition cash flow result operation substantial debt incur finance cash portion celgene myokardia acquisition assurance able expand business development capacity commit reduce debt pursue strategic transaction opportunity future require obtain additional equity debt financing result increase leverage andor downgrade credit rating failure attract retain highly qualified workforce affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management workforce include people expertise clinical rd governmental regulation commercialization ii connection acquisition integrate corporate culture maintain employee morale face increase competition limit pool qualified individual numerous pharmaceutical biotechnology company university government entity research institution company seek enter healthcare space company industry sure able retain quality talent cost materially increase market liquidity credit risk significant indebtedness negative consequence acquisition celgene myokardia increase debt result additional interest expense reduce financial flexibility continue capital investment develop new product declare future dividend adverse change global economic political condition adversely affect operation profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside global economic downturn create amplify variety risk business negatively affect growth addition uncertainty credit capital market impact growth strategy revenue earning cash flow expose risk strengthen dollar global inflation include operating cost significantly increase result rise inflation rate wage increase factor adversely affect revenue profitability exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union eu particular exit uk eu occur january create uncertainty affect business operation uk eu impact research commercial general business operation uk eu include approval supply product require change legal entity structure uk eu additionally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war pandemic epidemic covid pandemic affect demand product drive low patient start visit expect future pandemic similar effect addition experience significant manufacturing supply issue covid possible experience issue response future pandemic instance experience scarcity certain raw material component result influx pandemic relate vaccine order receive priority treatment vendor furthermore future epidemic pandemic create material staffing shortage manufacture site disrupt supply product possible experience supply chain interruption result quarantine shelterinplace governmental order policy travel restriction airline cargo capacity route reduction experience delay initiation enrollment patient clinical trial consequence future pandemic able fully mitigate delay negatively impact time pipeline development program expect future revenue andor cash flow prolong clinical trial delay potentially significant negative effect business particularly new competitive product enter market clinical trial result competitor product affect value proposition product delay difficulty clinical development potentially lead material impairment intangible asset include billion intangible asset december predict reasonably estimate impact potential longterm change healthcare industry global economic political event include future pandemic example potential shift payer channel mix change patient coverage current economic crisis able reliably estimate impact result operation give highly variable uncertain situation possible change healthcare system impose additional burden clinical trial increase cost sponsor clinical trial lead additional delay difficulty complete clinical trial experience additional pricing pressure andor increase governmental regulation global economic condition event war pandemic create additional risk impact supplier vendor outsource partner alliance partner party rely research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional services example thirdparty provider suffer limited solvency global economic condition negatively impact operating model business similarly global event ukrainerussia conflict increase volatility financial market foreign currency exchange interest rate face potential negative consequence stem future pandemic global event include limited increase cyber threat partner phishe social engineering malware attack possible global economic political event include future pandemic exacerbate risk describe guarantee pay dividend repurchase stock declaration time dividend fall discretion board board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market reduce number share repurchase share repurchase program adversely affect stock price ira impose excise tax net repurchase share december imposition excise tax repurchase share increase cost make repurchase cause board reduce number share repurchase pursuant share repurchase program amend bylaw designate court chancery state delaware sole exclusive forum certain lawsuit stockholder limit stockholder ability obtain judicial forum find favorable lawsuit costly stockholder bring lawsuit effect discourage lawsuit amend bylaw provide consent write selection alternative forum court chancery state delaware full extent permit law sole exclusive forum derivative action proceeding bring behalf ii action assert claim breach fiduciary duty owe director officer employee stockholder creditor constituent iii action assert claim arise pursuant provision general corporation law state delaware amend restate certificate incorporation amend bylaw iv action assert claim director officer employee govern internal affair doctrine provide event court chancery state delaware lack jurisdiction action proceed sole exclusive forum action proceed state federal court state delaware bylaw provide person entity purchase acquire hold interest share capital stock deem notice consent forum selection provision court chancery state delaware court chancery jurisdiction state federal court state delaware full authority allow law issue antisuit injunction enforce forum selection clause preclude suit forum forum selection provision intend apply action bring securities act securities act amended exchange act section exchange act create exclusive federal jurisdiction suit bring enforce duty liability create exchange act rule regulation thereunder section security act create concurrent jurisdiction federal state court suit bring enforce duty liability create security act rules regulation thereunder accordingly forum selection provision amend bylaw relieve duty comply federal security law rule regulation thereunder stockholder deem waive compliance law rule regulation forum selection provision bylaw limit stockholder ability bring claim judicial forum find favorable dispute director officer employee discourage lawsuit respect claim stockholder deem waive compliance federal security law rule regulation thereunder addition stockholder bring claim court chancery state delaware face additional litigation cost pursue claim particularly reside near delaware believe risk court decline enforce forum selection provision contain amend bylaw low court find provision inapplicable unenforceable respect specify type action proceeding incur additional cost associate resolve action jurisdiction harm business operating result financial condition item b unresolved staff comment item property principal executive office locate east th street th floor new york ny lease manufacturing rd administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer good operating condition provide adequate production capacity current project operation believe property subject material encumbrance easement restriction detract materially value impair use operation business information manufacturing property refer item businessmanufacture quality assurance significant manufacturing rd location geographic area follow december manufacturing rd united states europe total item legal proceeding information pertain legal proceeding find item financial statement supplementary datanote legal proceeding contingency incorporate reference item safety disclosure applicable ia information executive officer list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting shareholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio md chief executive officer director company chairman board chief executive officer present chairman board chief executive officer member leadership team christopher boerner phd president head commercial executive vice president chief commercialization officer president head international market member leadership team present executive vice president chief commercialization officer david v elkins group vice president chief financial officer consumer consumer medicine executive vice president chief financial officer johnson johnson member leadership team worldwide vice president chief financial officer consumer product medical development corporate function johnson johnson chief financial officer celgene corporation present executive vice president chief financial officer sharon greenlee vice president investor relations abbvie inc senior vice president corporate controller head price commercial abbvie inc head supply chain finance abbvie inc vice president controller rd finance operations abbvie inc present senior vice president corporate controller samit hirawat md executive vice president head oncology development novartis executive vice president chief medical officer global drug present executive vice president chief medical officer global drug development development member leadership team sandra leung present executive vice president general counsel executive vice president general counsel member leadership team greg meyers corporate vice president chief information officer motorola solutions executive vice president chief digital technology officer group chief information digital officer syngenta group member leadership team present executive vice president chief digital technology officer elizabeth mily manage director barclays investment bank executive vice president strategy business development present executive vice president strategy business development member leadership team ann powell senior vice president chief human resource officer executive vice president chief human resource officer present executive vice president chief human resource officer member leadership team karin shanahan senior vice president chief operating officer global operation teva pharmaceutical executive vice president global product development supply senior vice president global biologics sterile operation merck member leadership team present executive vice president global product development supply rupert vessey bm bch frcp dphil president research early development celgene corporation executive vice president president research executive vice president president research early development member leadership team present executive vice president president research michelle weese founderchief executive officer stratigence inc executive vice president corporate affairs general secretary north america danone member leadership team present executive vice president corporate affairs ii item market registrant common equity relate stockholder matter issuer purchase equity securities bristol myers squibb common stock trade new york stock exchange symbol bmy holder common stock number record holder common stock january number record holder base actual number holder register book date base information provide eq shareowner service transfer agent include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company equity compensation plan information information require item contain proxy statement head item vote uponitem advisory vote approve compensation name executive officersequity compensation plan information information incorporate reference performance graph follow graph compare cumulative total stockholder return common share cumulative total stockholder return company list standard poor index sp index composite peer group major pharmaceutical company comprise abbvie amgen astrazeneca biogen gilead glaxosmithkline johnson johnson lilly merck novartis pfizer roche sanofi graph assume investment december common share sp index stock peer group company include reinvestment dividend year end december stock price performance follow graph necessarily indicative future stock price performance bristol myers squibb sp peer group issuer purchase equity security follow table summarize surrender equity security month end december total number share approximate dollar value purchase share total number average price pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program b board director authorize repurchase billion common stock follow authorization board subsequently approve additional authorization include recently february january december billion billion billion respectively share repurchase authorization remain share repurchase capacity program approximately billion december refer item financial statement note equity information share repurchase program item reserve item management discussion analysis financial condition result operation management discussion analysis financial condition result operation provide supplement read conjunction consolidate financial statement relate note include enhance understanding result operation financial condition cash flow comparison result omit incorporate reference year end december item management discussion analysis financial condition result operation file february executive summary bristolmyers squibb company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end definition capitalize term document obtain approval new medicine additional indication formulation currently market medicine major market eu japan include advancement oncology fda ec approval opdualag pd inhibitor lag block antibody combination additionally eu japan opdivo base regimen firstline treatment unresectable advanced metastatic escc approve continue advance invest cell therapy portfolio approval abecma japan treatment multiple myeloma patient prior therapy approval breyanzi relapse refractory diffuse large bcell lymphoma secondline treatment japan thirdline treatment eu continue expansion cell therapy manufacturing capability exist facility washington new jersey construction new stateoftheart manufacturing facility massachusetts leiden netherlands approvals sotyktu deucravacitinib japan treatment moderate severe plaque psoriasis expand portfolio immunology cardiovascular broaden new product portfolio fda approval camzyos mavacamten patient symptomatic obstructive hcm addition august acquire turning point precision oncology company goal expand solid tumor portfolio addition repotrectinib revenue remain consistent prior year growth inline product primarily eliquis opdivo new product portfolio primarily opdualag abecma reblozyl offset recent loe product primarily revlimid impact foreign exchange decrease gaap ep primarily change equity investment contingent consideration fair value adjustment partially offset low impairment charge weightedaverage common share outstanding adjust specify item nongaap eps increase result lower weightedaverage common share outstanding acquire iprd charge high royalty license income highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earning share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation change nongaap financial measure refer nongaap financial measure economic market factor governmental action product continue subject increase pressure portfolio pharmaceutical market access pricing control discount change tax importation law restriction eu region world result low price low reimbursement rate small population payer reimburse negatively impact result operation include intangible asset impairment charge operate cash flow liquidity financial flexibility example august president biden sign ira provide government negotiate price select highcost medicare begin b drug begin year smallmolecule drug year biological product fda approval ii manufacturer pay rebate medicare b drug price increase fast inflation begin b iii medicare redesign replace current coverage gap provision establish cap outofpocket limit cost medicare beneficiary begin manufacturer responsible cost cap cap reach implementation legislation expect carry upcoming action regulatory authority outcome uncertain additionally connection ira follow change tax law include minimum tax generally apply corporation adjust financial statement income begin ii nondeductible excise tax provision net stock repurchase apply repurchase begin continue evaluate impact ira legislation result operation possible change result material impact business result operation furthermore country expect change tax law update international tax treaty implement agreement organization economic cooperation development establish global minimum tax risk factor item include iitem risk factorsproduct industry operational risksincreased pricing pressure restriction abroad continue negatively affect revenue profit margin change tax regulation negatively impact earning covid response covid pandemic international federal state local public health governmental authority take number action limit spread covid address relate disruption global economy covid pandemic affect global healthcare system major economic financial market adopt procedure focus ensure continued supply medicine patient protect health wellbeing safety workforce pandemic significantly impact result operation situation remain dynamic difficult reasonably assess predict extent negative impact covid pandemic business financial condition result operation cash flow significant product approval follow summary significant approval receive product date approval japan ministry health labour welfare approval breyanzi allow use secondline breyanzi december treatment relapse refractory large bcell lymphoma regardless autologous hematopoietic stemcell transplantation intend japan ministry health labour welfare approval sotyktu treatment plaque psoriasis sotyktu september generalize pustular psoriasis erythrodermic psoriasis patient inadequate response conventional therapy fda approval sotyktu treatment adult moderatetosevere plaque psoriasis sotyktu september candidate systemic therapy phototherapy ec approval opdualag firstline treatment advance unresectable metastatic melanoma opdualag september adult adolescent year age old tumor cell pdl expression fda approval breyanzi treatment adult patient relapse refractory large bcell lymphoma breyanzi june line therapy eligible transplant relapse month firstline chemoimmunotherapy product date approval japan ministry health labour welfare approval opdivo plus yervoy firstline treatment opdivoyervoy adult patient unresectable advanced metastatic escc regardless pdl status japan ministry health labour welfare approval opdivo combination fluoropyrimidine opdivo platinumcontaine chemotherapy firstline treatment adult patient unresectable advanced metastatic escc regardless pdl status fda approval opdivo plus yervoy firstline treatment adult patient unresectable opdivoyervoy advance metastatic escc regardless pdl status fda approval opdivo combination fluoropyrimidine platinumcontaine chemotherapy opdivo firstline treatment adult patient unresectable advanced metastatic escc regardless pdli status camzyos april fda approval camzyos treatment adult symptomatic obstructive hcm ec approval breyanzi treatment adult patient relapse refractory diffuse large bcell breyanzi april lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b line systemic therapy ec approval opdivo plus yervoy firstline treatment adult patient unresectable opdivoyervoy april advanced recurrent metastatic escc tumor cell pdl expression ec approval opdivo adjuvant treatment adult muscleinvasive urothelial carcinoma opdivo april tumor cell pdli expression risk recurrence undergo radical resection ec approval opdivo combination fluoropyrimidine platinumbase chemotherapy opdivo april line treatment adult patient unresectable advanced recurrent metastatic escc pdl expression fda approval opdualag fixeddose combination nivolumab relatlimab treatment opdualag march adult pediatric patient year age old unresectable metastatic melanoma fda approval opdivo combination platinumdoublet chemotherapy adult patient opdivo march resectable nsclc neoadjuvant set japan ministry health labour welfare approval opdivo adjuvant treatment urothelial opdivo march carcinoma japans ministry health labour welfare approval abecma treatment adult patient abecma january relapse refractory multiple myeloma receive prior therapy refer product pipeline development development market product latestage pipeline early strategy principal strategy combine resource scale capability large pharmaceutical company speed agility focus innovation typically find biotech industry priority continue renew diversify portfolio launch new medicine advance early mid late stage pipeline execute disciplined business development remain committed maintain strong investment grade credit rating return capital shareholder focus discover develop deliver transformational medicine patient face disease follow core therapeutic area oncology priority certain tumor type ii hematology opportunity broaden franchise sustain leadership position multiple myeloma iii immunology priority relapse multiple sclerosis psoriasis psoriatic arthritis lupus ra inflammatory bowel disease iv cardiovascular disease v fibrotic disease priority lung liver vi neuroscience focus neurodegenerative disease continue advance wave innovative medicine invest significantly oncology hematology alnuctamab multiple myeloma immunology lpa antagonist pulmonary fibrosis cardiovascular portfolio alliance partnership janssen advance generation antithrombotic medicine milvexian expand oncology portfolio include precision oncology asset repotrectinib ros mutate nsclc hematology broad effort continue address unmet medical need multiple myeloma lymphoma anemia eg mds mf associate anemia work multiple modality mechanism action cereblon modulator celmod adcs tcell engager cart therapy immunology phase iii clinical trial underway cendakimab eosinophilic esophagitis commercial model successful revenue inline brand new product portfolio continue grow demonstrate strong execution strategy launch firstinclass medicine blockbuster potential therapeutic area opdualag line melanoma camzyos ohcm sotyktu moderate severe psoriasis remain focused wellresourced cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave oncology mechanism develop treatment option refractory oncology patient strengthen io portfolio opdualag treatment melanoma potential expand opportunity lung liver crc adjuvant melanoma continue drive adoption opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription globally immunology phase iii registrational clinical trial underway sotyktu systemic lupus erythematosus sle psoriatic arthritis able leverage lead capability hematological malignancy robust pipeline provide opportunity longterm growth offset impact current future patent expire revlimid pomalyst expect growth inline new product portfolio enable offset expect decline revlimid abraxane product revenue loss market exclusivity evolution operating model focus maintain discipline approach marketing sell administrative expense enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio celgene acquisition restructuring activity realize billion synergy annually result cost saving avoidance achieve synergy general administrative manufacturing rd procurement result streamline company pricing information technology infrastructure strategy extend discovery development delivery transformative medicine help patient prevail disease believe drive longterm business value heart living purpose improve access affordability advance inclusion diversity health equity area medicine support healthy planet order sustain live community environmental social governance esg strategy integrate company core strategy opportunitie potential impact esg issue directly connect business esg strategy focus operate effective governance high ethical standard seek transparency dialogue stakeholder improve understand need ii foster environment inclusion belong build globally diverse workforce drive equitable advancement outcomes iii globe improve access innovative therapy promote health equity improve health outcome population disproportionately affect disease iv understand responsibility create maximum positive impact minimize environmental footprint leverage sustainability drive innovation build resiliency manage nonfinancial risk acquisition divestiture license arrangement detail information significant acquisition divestiture collaboration license arrangement refer item financial statement supplementary datum note alliance note acquisition divestitures license arrangement result operation regional revenue composition change revenue follow year end december vs dollar million change foreign exchangeb united states international othera total revenue include royalty alliancerelate revenue product sell regional commercial organization b foreign exchange impact derive apply prior period average currency rate current period revenue united states revenue increase primarily eliquis new product portfolio opdivo partially offset recent loe product average net selling price increase compare period year ago international international revenue decrease primarily low demand revlimid result generic erosion foreign exchange low average net selling price partially offset inline product new product portfolio single country outside contribute total revenue business typically seasonal gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy activity end reserve balance significant category gtn adjustment follow year end december rebate chargeback medicaid return discount dollar million cash discount medicare rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow year end december change dollar million vs gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus reduction provision product sale prior period result change estimate million million respectively reduction provision primarily relate nonus revision clawback amount primarily drive vat recoverable estimate eliquis coverage gap discount gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment percentage increase primarily high government channel mix high gtn adjustment percentage product revenue year end december dollar million change inline product eliquis nonus opdivo nonus pomalystimnovid nonus orencia nonus sprycel nonus yervoy nonus empliciti nonus mature product nonu new product portfolio reblozyl nonus abecma nonus opdualag na na nonus na zeposia nonus year end december change dollar million vs breyanzi nonus onureg nonu inrebic nonus camzyo na na nonus na sotyktu na na nonus na recent loe productsa revlimid nonus abraxane nonus total revenue nonus change excess recent loe product include product significant decline revenue prior reporting period result loss exclusivity eliquis apixaban oral factor xa inhibitor indicate reduction risk strokesystemic embolism nvaf treatment dvtpe reduction risk recurrence follow initial therapy revenue increase high demand high average net selling price include favorable gtn adjustment international revenue decrease primarily foreign exchange impact low average net selling price partially offset high demand exclude foreign exchange impact revenue increase follow expiration regulatory exclusivity eliquis europe court decision united kingdom find uk apixaban composition matter patent relate spc invalid ii netherlands deny bms request preliminary injunction prevent atrisk generic launch generic manufacturer begin market generic version eliquis uk netherlands seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe believe innovative science eliquis strength intellectual property defend infringement refer item financial statementsnote legal proceeding contingency intellectual property information opdivo nivolumab fully human monoclonal antibody bind pd nkt cell approve anticancer indication include bladder blood crc head neck rcc hcc lung melanoma mpm stomach esophageal cancer opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc gastric esophageal cancer ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent revenue increase high demand multiple indication include opdivoyervoy combination nsclc opdivocabometyx combination kidney cancer bladder gastric esophageal cancer partially offset decline secondline eligibility tumor indication increase competition international revenue increase high demand partially offset foreign exchange impact low average net selling price exclude foreign exchange impact revenue increase pomalystimnovid pomalidomide proprietary distinct small molecule administer orally modulate immune system biologically important target pomalystimnovid indicate patient multiple myeloma receive prior therapy include lenalidomide proteasome inhibitor demonstrate disease progression day completion therapy revenue increase high average net selling price high demand international revenue decrease foreign exchange impact low average net selling price partially offset high demand exclude foreign exchange impact revenue increase orencia abatacept fusion protein indicate adult patient moderate severe active ra psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular jia revenue increase high demand international revenue decrease foreign exchange impact partially offset high demand exclude foreign exchange impact revenue increase eu estimate minimum market exclusivity date previously base method use patent expire formulation additional patent expire orencia biosimilar market eu japan sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment patient philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib mesylate treatment child adolescent aged year year chronic phase philadelphia chromosomepositive cml revenue increase high average net selling price high demand international revenue decrease foreign exchange impact low demand result generic erosion exclude foreign exchange impact revenue decrease yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma opdivoyervoy regimen approve multiple market treatment nsclc melanoma mpm rcc crc esophageal cancer revenue increase high average net selling price international revenue increase high demand result additional indication launch core indication partially offset foreign exchange impact low average net selling price exclude foreign exchange impact revenue increase empliciti elotuzumab humanized monoclonal antibody treatment multiple myeloma mature product include product include lose exclusivity major market otc product royalty revenue mature product international revenue mature product decrease low demand result continue generic erosion foreign exchange impact exclude foreign exchange impact revenue decrease reblozyl luspaterceptaamt erythroid maturation agent indicate treatment anemia adult patient beta thalassemia require regular red blood cell transfusion treatment anemia fail esa adult patient low intermediaterisk mds ring sideroblast require rbc transfusion revenue increase primarily high demand abecma idecabtagene vicleucel bcell maturation antigendirecte genetically modify autologous cart cell therapy indicate treatment adult patient relapse refractory multiple myeloma prior line therapy include immunomodulatory agent proteasome inhibitor anticd monoclonal antibody abecma launch opdualag nivolumab relatlimabrmbw combination nivolumab pd block antibody relatlimab lag blocking antibody indicate treatment adult pediatric patient year age old unresectable metastatic melanoma opdualag launch march zeposia ozanimod oral immunomodulatory drug treat relapse form multiple sclerosis include clinically isolate syndrome relapsingremitte disease active secondary progressive disease adult treat moderately severely active uc adult zeposia launch june breyanzi lisocabtagene maraleucel cddirecte genetically modify autologous cart cell therapy indicate treatment adult patient certain type relapse refractory large bcell lymphoma line systemic therapy breyanzi launch april onureg azacitidine oral hypomethylate agent incorporate dna rna indicate continued treatment adult patient aml achieve complete remission complete remission incomplete blood count recovery follow intensive induction chemotherapy able complete intensive curative therapy onureg launch september inrebic fedratinib oral kinase inhibitor indicate treatment adult patient intermediate highrisk primary secondary postpolycythemia vera postessential thrombocythemia myelofibrosis inrebic launch august camzyos mavacamten cardiac myosin inhibitor indicate treatment adult symptomatic obstructive hcm improve functional capacity symptom camzyo launch april sotyktu deucravacitinib oral selective allosteric tyrosine kinase inhibitor indicate treatment adult moderatetosevere plaque psoriasis candidate systemic therapy phototherapy sotyktu launch september revlimid lenalidomide oral immunomodulatory drug combination dexamethasone indicate treatment patient multiple myeloma revlimid single agent indicate maintenance therapy patient multiple myeloma follow autologous hematopoietic stem cell transplant revenue decrease low demand drive generic erosion partially offset high average net selling price international revenue decrease low demand result generic erosion european country canada low average net selling price foreign exchange impact exclude foreign exchange impact revenue decrease certain party grant volumelimite license sell generic lenalidomide begin march pursuant license generic enter expect enter market volumelimite quantity generic lenalidomide eu generic lenalidomide product enter market japan composition matter patent expire july bms aware generic approval global revenue revlimid expect decline approximately billion abraxane paclitaxel albuminbound particle injectable suspension solventfree proteinbound chemotherapy product combine paclitaxel albumin proprietary nab technology platform treat breast cancer nsclc pancreatic cancer revenue decrease primarily entry authorize generic low demand authorize generic arrangement include product supply sale profit sharing fee international revenue decrease low demand result generic erosion foreign exchange impact exclude foreign exchange impact revenue decrease eu generics enter market japan estimate minimum market exclusivity date base method use patent estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject de minimis exception product wholesaler distribution channel outside direct customer distribution channel estimate level inventory excess month december september outside generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product year end december factor influence estimate include generic erosion seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process camzyos available restrict program call camzyos rem program product distribution limit rem certify pharmacy enrol pharmacy dispense patient authorize receive camzyos revlimid pomalyst distribute primarily contract pharmacy lenalidomide rem pomalyst rem program respectively proprietary riskmanagement distribution program tailor specifically provide safe appropriate distribution use revlimid pomalyst internationally revlimid imnovid distribute mandatory riskmanagement distribution program tailor meet local authority specification provide product safe appropriate distribution use program vary country depend country design riskmanagement program product sell hospital retail pharmacy nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior filing disclose product level inventory excess month hand expect demand subject de minimis exception quarterly report form q expense year end december change dollar million vs cost product solda marketing sell administrative research development acquire iprd amortization acquire intangible asset incomeexpense net total expense change excess exclude amortization acquire intangible asset cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss impairment charge cost product sell typically varies period result volume product mix particularly royaltie profit share foreign exchange change price inflation cost attribute manufacturing site exit impairment charge cost product sell exclude amortization acquire intangible asset cost product sell increase million primarily drive product mix include high profit sharing eliquis revenue growth million high manufacturing startup cost inventory relate charge primarily expand cart cell therapy capability partially offset foreign exchange relate hedging settlement million impairment charge relate inrebic eu regulatory approval milestones million marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion cost expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense increase million primarily higher charitable give million cash settlement turn point unvested stock award million partially offset foreign exchange research development research development activity include research early discovery preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time iprd impairment charge research development expense decrease million primarily lower iprd impairment charge million partially offset cash settlement turn point unvested stock award million refer item financial statement supplementary datanote goodwill intangible asset information impairment charge acquire iprd acquire iprd expense comprise upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval acquire iprd charge detailed table year end december dollar millions mavacamten royalty extinguishment dragonfly milestone optin license fee immatic upfront license fee bridgebio upfront collaboration fee eisai upfront collaboration fee agenu upfront license fee milestone prothena optin license fee evotec optin license fee acquire iprd refer item financial refer item financial statement supplementary datanote alliance note acquisition divestiture license arrangement additional information amortization acquire intangible asset amortization acquire intangible asset decrease million compare primarily change expect expiration market exclusivity period pomalyst quarter expiration abraxane market exclusivity fourth quarter incomeexpense net incomeexpense net change billion primarily equity investment contingent value right item discuss component incomeexpense net follow year end december dollar million interest expense royalty licensing income royalty income divestiture equity investment lossesincome net integration expense loss debt redemption divestiture gain litigation settlement investment income provision restructure contingent consideration incomeexpense net interest expense decrease additional debt maturity refer item financial statement supplementary datanote financing arrangement information royalty increase primarily high keytruda diabetes business divestiture royalty refer item financial statement supplementary datanote acquisition divestiture license arrangement information equity investment generate loss compare income fair value adjustment investment readily determinable fair value observable price change investment readily determinable fair value result primarily initial public offering thirdparty acquisition entity hold ownership interest change limit partnership net asset value refer item financial statement supplementary datanote financial instrument fair value measurement information integration expense decrease low consulting fee implement celgene integration initiative relate process system loss debt redemption result early redemption longterm debt billion billion divestiture gain result certain mature product right divest investment income increase primarily high interest rate litigation settlement include amount relate commercial dispute license supply obligation matter intellectual property promotional practice matter addition include income million result settlement resolve legal claim business interest pertain nimbus tyk inhibitor settlement provide contingent development regulatory salesbase milestone payable bms occurrence certain event refer item financial statementsnote legal proceeding contingency provision restructuring include exit cost primarily related celgene acquisition plan achieve billion annual synergy relate celgene acquisition plan refer item financial statement supplementary datanote restructure information contingent consideration primarily include fair value adjustment result change trade price contingent value right issue celgene acquisition contractual obligation pay contingent value right terminate january fda approve lisocel jcar december include foreign exchange loss million million net hedge exit cost million result transition commercial operation russian federation thirdparty distributor turn point acquisition cost million income taxis year end december dollar million earning income taxis provision income taxis effective tax rate impact specify item effective tax rate exclude specify item income tax impact attribute gaap effective tax rate include impact specify item summarize follow nongaap financial measure section income tax impact specify item primarily low jurisdictional tax rate attribute intangible asset amortization periods iprd impairment charge nontaxable contingent value right fair value adjustment revaluation less extent basis intangible asset internally transfer streamline legal entity structure celgene acquisition tax reserve release relate mead johnson splitoff transaction decrease effective tax rate exclude specify item primarily result release income tax reserve million tax position effectively settle bms tax year exclude mead johnson relate amount specify lapse statute limitation celgene tax year partially offset jurisdictional earning mix refer item financial statement supplementary datanote income taxis additional information nongaap financial measure nongaap financial measure nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative past future operating result item exclude nongaap earning relate eps information company believe relate ordinary course company business reflect company underlie business performance similar charge gain recognize prior period likely reoccur future period include amortization acquire intangible asset include product right generate significant portion ongoing revenue recur intangible asset fully amortize ii unwind inventory purchase price adjustment iii acquisition integration expense iv restructuring cost v accelerated depreciation impairment property plant equipment intangible asset vi divestiture gain loss vii stock compensation result acquisitionrelate equity awards viii pension legal contractual settlement charge ix equity investment contingent value right fair value adjustment include fair value adjustment attribute limited partnership equity method investment x amortization fair value adjustment debt acquire celgene exchange offer item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate certain significant tax item exclude impact result release income tax reserve relate mead johnson splitoff transaction internal transfer intangible asset streamline legal entity structure subsequent celgene acquisition provide international revenue priority product exclude impact foreign exchange calculate foreign exchange impact convert currentperiod local currency financial result prior period average currency rate compare adjust amount currentperiod result reconciliation nongaap measure comparable gaap measure include exhibit form k file february incorporate reference begin quarter significant rd charge income result upfront contingent milestone payment connection asset acquisition license thirdparty intellectual property right long exclude nongaap financial measure change presentation nongaap financial measure follow comment discussion sec purpose comparability nongaap financial measure year end december update reflect change nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understand underlying financial performance facilitate comparison current past future period information intend consider isolation substitute relate financial measure prepare accordance gaap comparable similarly title measure present company possible difference method item adjust encourage investor review financial statement publiclyfile report entirety rely single financial measure specify item follow year end december dollar million inventory purchase price accounting adjustment intangible asset impairment site exit cost cost product sell employee compensation charge site exit cost marketing sell administrative iprd impairment inventory purchase price accounting adjustment employee compensation charge site exit cost research development amortization acquire intangible asset interest expensea equity investment lossesgain net integration expense loss debt redemption divestiture gain litigation settlement provision restructure contingent consideration incomeexpense net increase pretax income income taxis item income tax reserve release attribute mead johnson income taxis attribute internal transfer intangible asset income taxis increase net earning include amortization purchase price adjustment celgene debt reconciliation gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap weight average common share outstanding diluted diluted earning share attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net debt position follow december dollar million cash cash equivalent marketable debt security total cash cash equivalent marketable debt security shortterm debt obligation longterm debt net debt position liquidity capital resource regularly assess anticipate work capital need debt leverage ratio level debt maturity capital expenditure requirement dividend payout potential share repurchase future investment acquisition order maximize shareholder return efficiently finance ongoing operation maintain flexibility future strategic transaction regularly evaluate capital structure ensure financial risk adequate liquidity access low cost capital efficiently manage lead issuance additional debt security repurchase debt security prior maturity issuance repurchase common stock tax cut job act research development cost require capitalize amortize effective january result increase approximately billion tax payment compare believe exist cash cash equivalent marketable debt security cash generate operation year require issuance commercial paper sufficient satisfy anticipate cash need year include dividend capital expenditure milestone payment work capital income taxis restructure initiative business development acquisition repurchase common stock debt maturity approximately billion debt repurchase redemption tender offer december net debt position increase billion primarily common stock repurchase dividend billion turning point acquisition billion partially offset cash operating activity billion share repurchase program authorize board director allow repurchase bm common stock share effect open market privately negotiate transaction compliance rule b exchange act include rule b trading plan share repurchase program obligate repurchase specific number share specific expiration date suspend discontinue time repurchase approximately million share common stock billion include approximately million share billion asr program remain share repurchase capacity share repurchase program billion december refer item financial statement supplementary datanote equity additional information dividend payment billion billion dividend pay common share quarter dividend authorize quarterly basis board director commercial paper program issue maximum billion unsecured note maturity day date issuance commercial paper borrowing outstanding december issue aggregate principal billion repurchase aggregate principal billion primarily modify future debt maturity addition billion debt mature repay refer item financial statementsnote financing arrangement information december fiveyear billion revolve credit facility expire january extendable annually year consent lender facility provide customary term condition financial covenant provide backup liquidity commercial paper borrowing borrowing outstanding revolve credit facility december investment portfolio include marketable debt security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statement supplementary datum note finance arrangement information capital expenditure annual capital expenditure approximately billion million million expect approximately billion continue capital expenditure connection expansion cell therapy manufacturing capability research development facilityrelate activity contractual obligation offbalance sheet arrangement normal course business enter contract commitment obligate payment future information obligation relate debt income taxis lease arrangement provide item financial statement supplementary datanote accounting policy recently issue accounting standard note financing arrangement note income taxis note lease respectively commit aggregate billion potential contingent future research development milestone payment party inlicense asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict certain agreement provide salesbased milestone aggregate billion obligate pay achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statement supplementary datanote alliance note acquisition divestiture license arrangement information offbalance sheet arrangement material reasonably likely material financial condition result operation credit rating current longterm shortterm credit rating assign moodys investor service prime respectively stable longterm credit outlook current longterm shortterm credit rating assign standard poor respectively stable longterm credit outlook long term rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business billion change cash flow operating activity compare drive high tax payment billion primarily result research development expense capitalize amortize tax purpose turn point acquisitionrelate payment million high upfront research early discovery payment million time cash collection time vendor payment ordinary course business investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security original maturity great day time purchase proceed business divestiture include royalty sale maturity marketable security sale equity investment upfront contingent milestone payment license arrangement million change cash flow investing activity compare primarily acquisition turn point billion net cash acquire low proceed sale equity investment billion partially offset change marketable debt security hold billion lower acquire iprd payment million high proceed divestiture million financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing proceed exercise stock option issuance longterm debt borrowing million change cash flow financing activity compare primarily high repurchase common stock billion partially offset change net debt borrowing million sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form q period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure budget process give appropriate weight input come adequately document process establish companywide policy concern sale direct customer purpose comply consent include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard refer item financial statement supplementary datanote accounting policy recently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly affect financial condition result operation require difficult subjective complex judgment need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize follow step model identify customer contract ii identify contract performance obligation iii determine transaction price iv allocate transaction price performance obligation v recognize revenue performance obligation satisfied revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix eg medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience follow category gtn adjustment involve significant estimate judgment information obtain external source refer item financial statement supplementary datanote revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity b program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country customer offer cash discount incentive prompt payment generally approximate invoice sale price account receivable reduce estimate cash discount time sale discount typically take customer month medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount cms medicare beneficiarie coverage gap estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss market exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model estimate level inventory distribution channel project demand estimate product return present liability use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information acquisition intangible asset valuation certain judgment determine transaction account acquisition asset business combination determine substantially fair value gross asset acquire transaction concentrate single asset group similar asset transaction treat acquisition asset evaluate input process output associate acquire set activity asset asset transaction include input substantive process significantly contribute ability create output transaction treat acquisition business assessment conclude turn point transaction business combination myokardia transaction asset acquisition account business combination acquisition method accounting require asset acquire liability assume generally record fair value acquisition date excess consideration fair value net asset acquire record goodwill estimate fair value require significant judgment assumption transaction account acquisition asset goodwill record contingent consideration payment achievement developmental regulatory commercial milestone generally recognize acquisition date asset acquisition upfront payment allocate iprd project acquisition date expense alternative future use addition product development milestone expense achievement identifiable intangible asset measure respective fair value acquisition date generally engage independent thirdparty valuation firm assist determine fair value asset acquisition date fair value asset estimate discount cash flow model model require use follow significant estimate assumption identification product candidate sufficient substance require separate recognition estimate revenue operate profit relate commercial product product candidate eligible patient price market share estimate future revenue probability success unapproved product candidate additional indication commercial product resource require complete development approval product candidate time regulatory approval exclusivity appropriate discount rate product market participant income tax rate allocation expect synergies product believe fair value record intangible asset acquire base reasonable estimate assumption consider fact circumstance acquisition date impairment amortization longlive asset include intangible asset longlive asset include intangible asset property plant equipment review impairment event change circumstance indicate carry asset recoverable annually iprd intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include change competitive landscape early expect loss market exclusivity pricing reduction adverse regulatory change clinical study result delay failure obtain regulatory approval initial follow indication unanticipate development cost inability achieve expect synergy result cost saving avoidance high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation carrying value longlive asset exceed fair value asset write fair value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use estimate useful life longlive asset subjective require significant judgment patent life future plan external market factor longlive asset periodically review change fact circumstance result reduction estimate useful life asset require acceleration depreciation amortization impairment charge include cost product sell research development expense million billion billion refer item financial statement supplementary datanote goodwill intangible asset discussion analysis impairment charge income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance million billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own ii conversion mead johnson class b share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class b share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code internal revenue service assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation december determine position effectively settle release related reserve agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion initial public offering create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statement supplementary datanote accounting policy recently issue accounting standardsincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statement supplementary datanote accounting policy recently issue accounting standardscontingencie note income taxis note legal proceeding contingency product pipeline development rd program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage rd program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual rd expense year opdivo investigational compound market product represent great rd expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow latestage new indication development market product development latestage pipeline february product indication date development announce ec approval opdivo adjuvant treatment adult muscleinvasive urothelial april carcinoma tumor cell pdli expression risk recurrence undergo radical resection approval base result phase iii checkmate trial bladder ono alliance partner opdivo japan announce japan ministry health labour welfare approve opdivo adjuvant treatment urothelial carcinoma partial change approve march item manufacturing marketing approval approval base result phase iii checkmate ono trial ono alliance partner opdivo japan announce japan ministry health labour welfare approve opdivo combination fluoropyrimidine platinum contain chemotherapy line treatment adult patient previously untreate unresectable advanced metastatic escc pd l expression allrandomize population approval base phase iii checkmate trial onoca escc announce fda approval opdivo combination fluoropyrimidine platinum contain chemotherapy firstline treatment adult patient unresectable advanced metastatic escc regardless pdl status approval base phase iii checkmate trial opdivo announce ec approval opdivo combination fluoropyrimidine platinumbase chemotherapy april firstline treatment adult patient unresectable advanced recurrent metastatic escc pd l expression approval base result phase iii checkmate trial announce result phase iii checkmate k trial evaluate opdivo adjuvant set patient completely resect stage iib iic melanoma demonstrate statistically significant october clinically meaningful benefit recurrencefree survival risk recurrence death reduce versus placebo new safety signal observe announce phase iii pivot io trial meet primary endpoint progressionfree survival pfs objective response rate orr patient previously untreate unresectable melanoma metastatic melanoma treat bempegaldesleukin combination opdivo compare opdivo monotherapy dmc notify company primary endpoint overall survival os meet statistical significance interim analysis trial conduct collaboration march nektar trial unblinde additional analysis os endpoint perform base subsequent result preplanne analyse latestage clinical study rcc bladder cancer couple result pivot io note bms nektar jointly decide end global clinical development program bempegaldesleukin combination opdivo product indication date developments ono alliance partner opdivo japan announce company submit supplemental japanese nda pharmaceuticals medical devices agency opdivo expand use neoadjuvant april treatment resectable nsclc combination chemotherapy partial change approve item manufacture marketing approval japan application base phase iii checkmate study announce result phase iii checkmate trial show neoadjuvant treatment opdivo combination chemotherapy significantly improve eventfree survival primary endpoint april compare chemotherapy patient resectable nsclc opdivo combination chemotherapy nsclc reduce risk disease recurrence progression death demonstrate favorable early overall survival trend announce ema validate type ii variation application opdivo combination march chemotherapy neoadjuvant treatment patient resectable stage ib iiia nsclc opdivo application base result phase iii checkmate trial announce fda approval opdivo combination platinumdoublet chemotherapy treatment march adult patient resectable nsclc neoadjuvant set approval base phase iii checkmate trial announce alliance partner nektar base result preplanne analysis latestage clinical study bempegaldesleukin combination opdivo rcc bladder cancer jointly end april global clinical development program bempegaldesleukin combination opdivo study ongoing study program discontinue rcc announce twoyear followup result analysis phase iii checkmateer trial demonstrate february sustain survival response rate benefit healthrelate quality life improvement combination opdivo cabometyx versus sunitinib firstline treatment advance rcc announce phase iii checkmate trial evaluate opdivo plus yervoy adjuvant rcc july treatment patient localize rcc undergo partial removal kidney moderate high risk relapse meet primary endpoint diseasefree survival safety profile consistent previously report study opdivo plus yervoy combination solid tumor announce fiveyear follow result phase iii checkmate trial demonstrate longterm june durable survival outcome opdivo plus yervoy firstline treatment patient metastatic nsclc regardless pdl expression level primary endpoint population combination nearly double overall nsclc survival rate compare chemotherapy announce threeyear follow result phase iii checkmate la trial demonstrate longterm durable survival benefit opdivo plus yervoy cycle chemotherapy compare cycle june chemotherapy patient previously untreate metastatic nsclc regardless pdl expression histology announce result phase iii checkmate trial compare opdivo plus yervoy standardofcare opdivo yervoy chemotherapy firstline treatment patient untreate unresectable metastatic urothelial carcinoma bladder ineligible cisplatin base chemotherapy meet primary endpoint overall survival patient tumor cell express pdl final analysis trial continue assess primary secondary endpoint new safety signal observe time analysis ono alliance partner opdivo plus yervoy japan announce japan ministry health labour welfare approve opdivo combination fluoropyrimidine platinum contain chemotherapy firstline treatment adult patient previously untreate unresectable advanced metastatic escc pdl expression allrandomize population approval base phase iii checkmate trial escc announce fda approval opdivo plus yervoy firstline treatment adult patient unresectable advanced metastatic escc regardless pdl status approval base phase iii checkmate trial announce ec approval opdivo plus yervoy firstline treatment adult patient unresectable april advanced recurrent metastatic escc tumor cell pdl expression approval base result phase iii checkmate trial product indication date development announce initial result phase iii accelerate covid therapeutic intervention vaccine activ immune modulator clinical trial sponsor national institutes health show strong statistically significant improvement primary endpoint time recovery measure orencia covid june day hospital discharge analyse secondary endpoint include mortality clinical status demonstrate orencia reduce participant risk death improve clinical status day enter study compare placebo announce committee medicinal product human use chmp european medicine january agency ema recommend approval reblozyl treatment adult patient anemia associate nontransfusiondependent ntd beta thalassemia beta thalassemia announce withdrawal sbla reblozyl treatment anemia adult non transfusion dependent beta thalassemia appropriately address fda question june benefitrisk profile reblozyl patient population base current dataset phase ii reblozyl trial announce result phase iii command trial evaluate reblozyl meet primary endpoint mds october demonstrate highly statistically significant clinical meaningful improvement red blood cell transfusion independence concurrent hemoglobin increase firstline treatment adult patient low low intermediaterisk mds require red blood cell transfusion announce alliance partner seventy bio inc positive topline result phase iii karmma trial evaluate abecma compare standard combination regimen adult multiple myeloma august relapse refractory prior line therapy refractory regiman show abecma significantly improve progressionfree survival treatment abecma show improvement key secondary endpoint overall response rate compare standard regimen abecma multiple myeloma announce japan ministry health labour welfare approval abecma treatment adult patient relapse refractory multiple myeloma receive prior therapy include january immunomodulatory agent proteasome inhibitor anticd antibody experienced disease progression therapy relapse therapy approval base result phase ii bbmm phase crb trial announce retrospective analysis ongoing phase iii daybreak openlabel extension trial zeposia relapse ms show participant mount serologic response covid ms october follow vaccination covidrelate adverse event vaccinate participant nonserious post hoc analysis phase iii daybreak radiance trial demonstrate great proportion patient treat zeposia versus interferon betaa low annualize rate brain volume loss zeposia announce post hoc analysis phase iii true north study evaluate duration response follow continuous zeposia treatment year follow treatment interruption patient moderately uc october severely active uc achieve clinical response end induction period patient remain zeposia show disease relapse week disease control maintain week patient switch placebo initial response product indication date development announce positive topline result phase ii portion transcend cll phase iii january openlabel singlearm multicenter study evaluate breyanzi adult relapse refractory chronic lymphocytic leukemia small lymphocytic lymphoma study meet primary endpoint complete response rate compare historical control announce japan ministry health labour welfare approval breyanzi use secondline treatment relapse refractory large bcell lymphoma regardless autologous hematopoietic stemcell transplantation intend approval base result clinical trial patient december relapse refractory aggressive bcell nonhodgkin lymphoma firstline therapy include global phase iii clinical trial jcarbcm patient intend autologous hematopoietic stemcell transplantation phase ii clinical trial united state patient intend autologous hematopoietic stemcell transplantation cohort phase ii clinical trial jcarbcm europe japan announce fda approval breyanzi secondline treatment adult patient large bcell breyanzi lymphoma lymphoma include diffuse large bcell lymphoma specify highgrade bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b refractory disease june line chemoimmunotherapy relapse month firstline chemoimmunotherapy refractory disease firstline chemoimmunotherapy relapse firstline chemoimmunotherapy eligible hematopoietic stem cell transplant comorbiditie age approval base result phase ii pilot phase iii transform trial announce ema validate type ii variation application extension indication breyanzi secondline treatment adult patient diffuse large bcell lymphoma high grade bcell june lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b refractory relapse month initial therapy candidate hematopoietic stem cell transplant application base phase iii transform study announce ec approval breyanzi treatment adult patient relapse refractory diffuse large bcell lymphoma primary mediastinal large bcell lymphoma follicular lymphoma grade b april line systemic therapy approval base result transcend world transcend nhl trial announce ec approval fixeddose combination opdualag firstline treatment advance september unresectable metastatic melanoma adult adolescent year age old tumor cell pd l expression approval base result phase iiiii relativity trial opdualag melanoma announce fda approval opdualag nivolumab relatlimabrmbw fixeddose combination nivolumab relatlimab novel lag inhibitor treatment adult pediatric patient year march age old unresectable metastatic melanoma approval base result phase iiiii relativity trial announce fda accept supplemental nda camzyos expand indication october reduce need septal reduction therapy fda set target action date june supplemental nda base result phase iii valorhcm trial announce fda approval camzyos treatment adult symptomatic new york heart camzyos mavacamten obstructive hcm april association class iiiii obstructive hcm improve functional capacity symptom approval base result phase iii explorerhcm trial announce interim result explorerlte cohort mavalte trial patient april symptomatic obstructive hcm show sustained improvement cardiovascular function patient symptom week new safety signal observe product indication date development chmp ema recommend approval sotyktu treatment adult moderate january tosevere plaque psoriasis chmp recommendation review ec authority approve medicine ec announce japans ministry health labour welfare approval sotyktu treatment plaque psoriasis generalize pustular psoriasis erythrodermic psoriasis patient inadequate september response conventional therapy approval base result phase iii poetyk pso trial plaque psoriasis announce fda approval sotyktu treatment adult moderatetosevere plaque psoriasis september candidate systemic therapy phototherapy approval base result phase iii poetyk pso poetyk pso clinical trial sotyktu announce twoyear result poetyk pso longterm extension trial demonstrate clinical september efficacy maintain continuous sotyktu treatment adult patient moderatetosevere plaque psoriasis announce result phase ii paisley trial show statistically significant efficacy primary endpoint sle responder index response week patient moderatetosevere sle treat sotyktu versus placebo secondary endpoint demonstrate clinically meaningful sle june improvements week safety profile sotyktu consistent previously report study patient psoriasis psoriatic arthritis new safety signal observe datum demonstrate favorable riskbenefit profile supportive progressing phase iii special note forwardlooke statement include document incorporate reference write oral statement time time contain certain forward look statement meaning section security act section e exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation projection future financial result goal plan objective involve inherent risk assumption uncertainty include internal external factor delay divert change year cause future financial result goal plan objective differ materially express imply statement statement likely relate thing goal plan objective financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product business development strategy relation ability realize project benefit acquisition celgene myokardia turning point impact covid pandemic operation development commercialization product potential law regulation low drug price market action take private government payer manage drug utilization contain cost expiration patent datum protection certain product include assumption ability retain marketing exclusivity certain product outcome contingency legal proceeding financial result forwardlooke statement guarantee include important factor cautionary statement include particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date additional risk currently deem immaterial presently know cause forwardlooke event discuss occur require applicable law undertake obligation publicly update revise forwardlooke statement result new information future event change circumstance date item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward purchase local currency option contract manage risk primarily arise certain intercompany sale purchase transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate non dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange contract million million december december respectively reduce earning remain life contract crosscurrency interest rate swap contract manage risk arise longterm debt denominate euros hedge company net investment foreign subsidiary estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value crosscurrency interest swap contract million million december december expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain international affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive loss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statement supplementary datanote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt use cross currency interest rate swap contract designate manage risk arise longterm debt denominate euros hedge company net investment foreign subsidiary fair value contract marketable debt security analyze yearend determine sensitivity interest rate change sensitivity analysis increase shortterm longterm interest rate december december expect adverse impact earning material estimate increase longterm interest rate december december decrease fair value longterm debt billion billion respectively credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statement supplementary datanote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product solda marketing sell administrative research development acquire iprd amortization acquire intangible asset incomeexpense net total expense earningsloss income taxis provision income taxis net earningsloss noncontrolle interest net earningsloss attributable bms earningsloss common share basic dilute exclude amortization acquire intangible asset consolidate statement comprehensive incomeloss dollar millions year end december comprehensive incomeloss net earningsloss comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translation total comprehensive incomeloss comprehensive incomeloss comprehensive income attributable noncontrolle interest comprehensive incomeloss attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable debt security receivables inventory current asset total current asset property plant equipment goodwill intangible asset defer income taxis noncurrent asset total asset liability current liability shortterm debt obligation account payable current liability total current liability defer income taxis longterm debt noncurrent liability total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million common share total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earningsloss adjustment reconcile net earningsloss net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge divestiture gain royalty acquire iprd equity investment lossesgain net contingent consideration fair value adjustment adjustment change operate asset liability receivable inventory account payable rebate discount income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable debt security purchase marketable debt security proceed sale equity investment security capital expenditure divestiture proceed acquisition payment net cash acquire net cash investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend stock option proceed net net cash financing activity effect exchange rate cash cash equivalent restrict cash decreaseincrease cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year cash cash equivalent restrict cash end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard nature operation basis consolidation bristolmyer squibb company bms company global biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end definition capitalize term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function consistent bmss operational structure chief executive officer ceo chief operating decision maker manage allocate resource global corporate level manage allocate resource global corporate level enable ceo assess overall level resource available well deploy resource function therapeutic area regional commercial organization research development project line overarch longterm corporatewide strategic goal product franchise basis determination single segment consistent financial information regularly review ceo purpose evaluate performance allocate resource set incentive compensation target planning forecast future period information product regional revenue note revenue use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine accounting acquisition impairment intangible asset chargeback cash discount sale rebate return adjustment legal contingency income taxis actual result differ estimate reclassification certain reclassification conform prior period consolidated financial statement current period presentation upfront contingent milestone charge connection asset acquisition license thirdparty intellectual property right previously present research development present acquire iprd consolidate statement earning cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable debt security marketable debt security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity marketable debt security review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition equity investment equity investment readily determinable fair value record fair value change fair value record incomeexpense net equity investment readily determinable fair value record cost minus impairment plus minus change estimate fair value result observable price change orderly transaction identical similar investment issuer change estimate fair value equity investment readily determinable fair value record incomeexpense net bms hold investment limited partnership primarily invest earlystage life science company limit partnership investment measure proportionate share net asset value underlie investment hold limited partnership practical expedient investment typically redeemable distribution liquidation underlie asset investment own company limited partnership account equity method accounting ability exercise significant influence operate financial decision investee maintain proportional share investee net income loss equity investment account equity method include incomeexpense net equity investment readily determinable fair value equity investment account equity method assess potential impairment quarterly basis base qualitative factor inventory valuation inventory state low average cost net realizable value property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software range year acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition asset acquire meet definition business primarily significant process acquire substantially relative fair value allocate single asset transaction account asset acquisition business combination goodwill record addition asset acquisition acquire inprocess research development iprd asset alternative future use charge acquire iprd goodwill iprd intangible asset fair value acquire intangible asset determine incomebased approach refer excess earning method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success finitelive intangible asset include license market product right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize goodwill tested annually impairment assess qualitative factor determine likely fair value net asset carry amount example qualitative factor assess include bmss share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annually frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value derivative derivative instrument recognize asset liabilitie fair value consolidate balance sheet classify current longterm base scheduled maturity instrument derivative designate hedge assess inception quarterly determine highly effective offset change cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately effective portion change fair value derivative designate cash flow hedge report accumulate comprehensive loss subsequently recognize earning consistent underlying hedged item derivative long highly effective hedge company discontinue hedge account prospectively earning impact relate discontinued cash flow hedge hedge ineffectiveness material period present hedged forecast transaction probable occur gain loss reclassify accumulated comprehensive loss earning derivative designate hedge adjust fair value current earning company use derivative instrument foreign currency denominate debt hedge net investment certain foreign subsidiary affiliate realize unrealized gain loss hedge include foreign currency translation accumulate comprehensive loss derivative cash flow exception net investment hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item cash flow related net investment hedge classify investing activity restructure restructuring charge recognize result action streamline operation realize synergy acquisition reduce number facility estimate impact restructuring plan include future termination benefit integration expense exit cost require judgment actual result vary estimate restructure charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur revenue recognition refer note revenue detailed discussion accounting policy relate revenue recognition include defer revenue royalty refer note alliance detail alliance research development acquire iprd research development cost expense incur clinical study certain research cost recognize service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner nonrefundable advance payment service receive future use research development activity record prepay asset expense period service perform acquire iprd expense include upfront payment contingent milestone payment connection asset acquisition inlicense arrangement thirdparty intellectual property right upfront contingent milestone payable bms alliance partner prior regulatory approval company acquire iprd type transaction follow type transaction year end december dollar millions alliance note inlicense arrangement note asset acquisition note acquire iprd advertising product promotion cost advertising product promotion cost expense incurred advertising product promotion cost include marketing sell administrative expense billion million foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive incomeloss income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax effect global intangible lowtaxed income certain foreign subsidiary recognize income tax provision period tax arise tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement recently issue accounting standard adopt business combination october fasb issue amend guidance accounting contract asset contract liability contract customer business combination guidance intend address inconsistency relate recognition acquire contract liability payment term effect subsequent revenue recognize acquisition date entity account relate revenue contract accordance exist revenue recognition guidance generally assess acquiree apply recognition measurement financial statement amend guidance effective january prospective approach fair value measurement june fasb issue amend guidance measure fair value equity security subject contractual restriction prohibit sale equity security guidance clarify contractual restriction sale equity security consider unit account equity security consider measure fair value guidance clarify entity separate unit account recognize measure contractual sale restriction amendment require follow disclosure equity security subject contractual sale restriction fair value equity security subject contractual sale restriction reflect balance sheet nature remain duration restriction circumstance cause lapse restriction amend guidance effective january prospective basis early adoption permit note revenue follow table summarize disaggregation revenue nature year end december dollar million net product sale alliance revenues revenues total revenue net product sale represent total revenue period present product sell principally wholesaler distributor specialty pharmacy less extent directly retailer hospital clinic government agency customer order generally fulfil day receipt result minimal order backlog contractual performance obligation usually limit transfer control product customer transfer occur shipment receipt product consider customer obtain legal title product infusion cell therapie bms obtain right payment point customer able direct use obtain substantially remain benefit product gross revenue large pharmaceutical wholesaler percentage gross revenue follow year end december mckesson corporation amerisourcebergen corporation cardinal health inc wholesaler initially invoice contractual list price payment term typically day base customary practice country revenue reduce wholesaler list price time recognition expect chargeback discount rebate sale allowance product return gtn adjustment gtn adjustment attribute commercial arrangement manage healthcare organization government program medicare medicaid b program contain pricing implication mandatory discount pricing protection wholesaler list price discount medicare beneficiarie coverage gap addition nonus government program include different pricing scheme cost cap volume discount outcomebase pricing pricing clawback determine sale individual company aggregation company participate specific market chargeback cash discount reflect reduction receivables settle issuance credit customer typically month rebate discount adjustment include medicaid medicare reflect liability settle cash payment customer typically time period range month year significant judgment require estimate gtn adjustment consider legal interpretation applicable law regulation historical experience payer channel mix current contract price applicable program unbilled claim processing time lag inventory level distribution channel follow table summarize gtn adjustment year end december dollar millions gross product sale gtn adjustmentsa chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale include adjustment provision product sale prior period result change estimate million million million alliance revenue consist primarily amount relate collaboration outlicense arrangement arrangement evaluate represent contract scope revenue recognition guidance entirety contain aspect scope guidance directly reference base application guidance relate derecognition nonfinancial asset asc performance obligation identify separate party benefit directly right good service readily available resource right good service highly interdependent interrelate transaction price arrangement include fix upfront amount variable consideration contingent development regulatory milestone salesbase milestone royalty likely method estimate contingent development regulatory salesbase milestone ultimate outcome binary nature expect value method estimate royalty broad range potential outcome exist instance royalty relate license variable consideration include transaction price extent significant reversal cumulative revenue recognize probable occurring uncertainty associate variable consideration subsequently resolve significant judgment require estimating variable consideration recognize assess factor outside bmss influence likelihood regulatory success limited availability party information expect duration time resolution lack relevant past experience historical practice offering fee concession large number broad range possible amount extent arrangement include multiple performance obligation separable transaction price assign distinct performance obligation reflective relative standalone selling price recognize point time transfer control type outlicense arrangement typically utilize arrangement bms outlicense intellectual property party performance obligation ii arrangement include license additional performance obligation supply product request party iii collaboration arrangement include transfer license party jointly develop commercialize product outlicense arrangement consist single performance obligation satisfy execution agreement development commercialization right transfer party upfront fee recognize immediately include incomeexpense net contingent development regulatory milestone amount assess period likelihood achievement typically constrain recognize uncertainty subsequently resolve milestone include incomeexpense net salesbase milestone royalty recognize milestone achieve subsequent sale occur salesbased milestone royalty include alliance revenue certain outlicensing arrangement include contingent performance obligation supply commercial product party request license supply obligation account separate performance obligation consider distinct party benefit license supply resource readily available obligation separately identifiable obligation contract accordance revenue recognition guidance consider standalone selling price situation upfront fee contingent development regulatory milestone amount salesbase milestone royalty allocate license recognize manner describe consideration supply obligation usually base stipulate costplus margin contractual term represent standalone selling price supply consideration recognize point time transfer control product party include alliance revenues fee allocation license supply represent consideration expect entitle satisfaction separate performance obligation collaboration arrangement unique nature party active participant operating activity expose significant risk reward depend commercial success activity performance obligation inherent arrangement include transfer certain development commercialization right ongoing development commercialization service product supply obligation certain product supply obligation consider distinct account separate performance obligation similar manner discuss performance obligation consider distinct combine single performance obligation transfer right highly integrate interrelated obligation jointly develop commercialize product party result upfront fee recognize ratably time expect period collaboration activity include incomeexpense net license combine development commercialization obligation contingent development regulatory milestone long constrain recognize similar manner prospective basis royalty profit sharing recognize underlie sale profit occur include alliance revenue refer note alliance information follow table summarize disaggregation revenue product region year end december dollar millions inline product eliquis opdivo pomalystimnovid orencia sprycel yervoy empliciti mature brand new product portfolio reblozyl abecma opdualag zeposia breyanzi onureg inrebic camzyos sotyktu recent loe productsa revlimid abraxane total revenue united states international otherb total revenue recent loe product include product significant decline revenue prior reporting period result loss exclusivity b include royalty alliancerelate revenue product sell bmss regional commercial organization contract asset primarily estimate future royalty termination fee eligible licensing exclusion recognize asc asc contract asset reduce receivable increase period underlie sale occur cumulative catchup adjustment revenue affect contract asset contract liability material year end december revenue recognize performance obligation satisfy prior period million million million consist primarily revise estimate gtn adjustment relate prior period sale royalty outlicense arrangement sale commission incremental cost obtain customer contract expense incur amortization period year note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region bms refer collaboration alliance partner alliance partner common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bmss contractual share thirdparty sale andor royalty income include alliance revenues sale commercial product consider bmss ongoing major central operation refer note revenue information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenues sale commercial product consider bmss ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development regulatory approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms development copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense net activity perform time relate sale commercial product include bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation upfront contingent regulatory approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include acquire iprd expense royalty contingent consideration payable bms alliance partner relate divestiture business include incomeexpense net earn payment bms alliance partner present cash flow operating activity upfront milestone payment present cash flow investing activity select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development acquire iprd incomeexpense net select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone payment specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election statement earning classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment record deferred income amortize incomeexpense net eliquis commercial product commencement alliance upfront payment subsequent contingent milestone proceed amortize expect period bms copromotion obligation market exclusivity period party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms pfizer manufacture product alliance bms principal end customer product sale significant country europe canada australia china japan south korea certain small country pfizer commercialization right bms supply product pfizer cost plus percentage net sale price endcustomer record transfer control product pfizer summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing incomeexpense net amortization defer income select alliance balance sheet information december dollar million receivables account payable deferred income ono bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment nektar bms nektar discontinue global clinical development program bempegaldesleukin nktr combination opdivo base result preplanne analyse latestage clinical study rcc bladder cancer study ongoing study program discontinue research development cost reimbursement material bridgebio bms bridgebio commence collaboration develop commercialize bbp shp inhibitor oncology transaction include upfront payment million expense acquire iprd bridgebio eligible receive contingent development regulatory salesbase milestone million royaltie global net sale exclude certain market bridgebio responsible funding complete ongoing bbp phase monotherapy combination therapy trial bms lead fund development commercial activity bridgebio option co develop bbp receive high royalty seventy bio bms seventy bio jointly develop commercialize novel diseasealtering gene therapy product candidate target bcma collaboration include right bms license antibcma product result collaboration ii right seventy bio participate development commercialization license product result collaboration codevelopment profit share exchange reduction milestone payment iii salesbase milestone royalty payable seventy bio commercialization license product result collaboration seventy bio decline exercise codevelopment profit sharing right option license idecabtagene vicleucel abecma exercise profit loss relate develop commercialize manufacturing idecel share equally bms exclusively responsible development commercialization idecel outside fda approve abecma treatment relapse refractory multiple myeloma net product sale abecma million million relate profit sharing cost million million respectively cost reimbursement material term collaboration amend include certain manufacturing obligation party release future exclusivity relate bcmadirecte cell therapy bms pay million extinguish obligation future exus milestone royalty idecel expense acquire iprd eisai bms eisai commence exclusive global strategic collaboration codevelopment cocommercialization morab selective folate receptor alpha antibodydrug conjugate investigate endometrial ovarian lung breast cancer morab currently phase iii clinical trial solid tumor party jointly develop commercialize morab canada europe russia japan china certain country asiapacific region collaboration territory eisai responsible global manufacturing supply profit research development commercialization cost share collaboration territory bms responsible development commercialization outside collaboration territory pay royalty sale million upfront collaboration fee expense acquire iprd bms obligate pay billion achievement contingent development regulatory salesbase milestone cost reimbursement material note acquisition divestiture license arrangement acquisition turn point august bms acquire turn point billion cash billion net cash acquire turning point clinicalstage precision oncology company pipeline investigational medicine design target common mutation alteration drive cancer growth acquisition provide bms right turn point lead asset repotrectinib clinical preclinical stage asset transaction account business combination require asset acquire liability assume recognize fair value acquisition date total consideration acquisition consist follow dollar million total consideration cash consideration outstanding share cash consideration equity award consideration pay unvested stock award total consideration allocate include unvested equity award million expense marketing sell administrative million expensed research development purchase price allocation result follow amount allocate asset acquire liability assume acquisition date base respective fair value summarize purchase price dollar million allocation cash cash equivalent current asset intangible asset defer income tax asset noncurrent asset defer income tax liability current liability identifiable net asset acquire goodwill b total consideration allocate intangible asset primarily consist iprd allocate repotrectinib billion potential bestinclass tyrosine kinase inhibitor target ros ntrk oncogenic driver nsclc advanced solid tumor repotrectinib currently registrational phase ii study adult phase iii study pediatric patient estimate fair value iprd asset determine income approach valuation method b goodwill result primarily recognition defer tax liability deductible tax purpose result turn point operation include consolidated financial statement commence august material historical financial result acquire entity significant myokardia november bms acquire myokardia billion include cash settlement equity stock awards myokardia clinicalstage biopharmaceutical company pioneer precision medicine approach discover develop commercialize target therapy treatment cardiovascular disease acquisition provide bms right myokardia lead asset mavacamten potential firstinclass cardiovascular medicine treatment obstructive hypertrophic cardiomyopathy mavacamten approve fda april brand camzyos bms fund transaction combination cash hand operation net proceed receive connection senior unsecured note offer transaction account asset acquisition mavacamten represent substantially fair value gross asset acquire exclude cash defer income taxis result billion expense acquire iprd additionally connection acquisition bms record approximately billion asset primarily consist cash defer income taxis license liability assume million total consideration pay include million unvested stock award expense marketing sell administrative million research development million forbius bm acquire outstanding share forbius million contingent development regulatory salesbase milestone payment million forbius privately hold clinicalstage protein engineering company design develop biotherapeutic treatment cancer fibrotic disease acquisition provide bms right forbius tgfbeta program include program lead investigational asset avid phase development bms account transaction asset acquisition avid represent substantially fair value gross asset acquire result million expense acquire iprd million allocate defer tax asset divestiture follow table summarize financial impact divestiture include royalty income include incomeexpense net revenue pretax earning relate divestiture material period present exclude divestiture gain loss net proceedsa divestiture gainslosse royalty income dollar millions diabete business mature product total include proceed royalty receive subsequent relate sale asset business diabete business february bms astrazeneca terminate diabetes business alliance agreement bms sell astrazeneca substantially diabete business comprise alliance consideration transaction include tiere royalty payment range base net sale royalty million million million bm transfer percentage future royalty right amelyn onglyza farxiga net product sale party result transfer royalty income associate product reduce million million million mature product manufacturing operation january bms sell manufacturing facility syracuse new york lotte corporation result cash proceed million receive december business account heldforsale december asset reduce estimate relative fair value result million impairment charge record cost product sell asset liability reclassify heldforsale include current asset current liability million million respectively december product right mature product sell cheplapharm result cash proceed million divestiture gain million product right mature brand sell result proceed million divestiture gain million licensing arrangement royalty licensing income follow table summarize financial impact keytruda royalty tecentriq royalty upfront licensing fee milestone product obtain commercial approval include incomeexpense net year end december dollar million keytruda royalty tecentriq royalty upfront licensing fee contingent milestone income amortization defer income biohaven sublicense income royalty total keytruda patent license agreement bms ono enter global patent license agreement merck relate merck pd antibody keytruda accordance agreement merck obligate pay ongoing royalty global sales keytruda january december january december company grant certain right respective patent portfolio pertain pd payment royalty share bms ono percent allocation respectively adjust party legal fee tecentriq patent license agreement bms ono enter global patent license agreement roche group relate tecentriq roche antipdl antibody agreement roche pay million include royalty pay singledigit royalty worldwide net sale tecentriq december upfront payment royalty share bms ono consistent exist agreement bms record million incomeexpense net settlement inlicense arrangement immatic bm obtain global exclusive license immatic tcr bispecific m program m studied oncology clinical trial application approve german federal regulatory authority trial commence bms immatic collaborate development bms responsible commercialization m worldwide include strategic decision regulatory responsibility funding manufacture immatic option cofund development exchange enhance royalty payment andor copromote m transaction include upfront payment million expense acquire iprd addition immatic eligible receive contingent development regulatory salesbase milestone million royaltie global net sale agenu bms obtain global exclusive license agenu proprietary agen bispecific antibody program block tigit additional target agen study oncology phase clinical trial initiate october bms responsible development subsequent commercialization agen relate product worldwide include strategic decision regulatory responsibility funding manufacturing transaction include payment million include acquire iprd addition agenu eligible receive contingent development regulatory salesbase milestone billion royalty global net sale dragonfly bms obtain global exclusive license dragonfly interleukin il investigational immunotherapy program include extended halflife cytokine df bms responsible development subsequent commercialization df relate product worldwide include strategic decision regulatory responsibility funding manufacturing dragonfly continue involve development df current certain future phase iii clinical trial bms pay million dragonfly right expense acquire iprd payment include million follow commencement phase combination clinical study dragonfly eligible receive additional contingent consideration comprise development regulatory salesbase milestone payment billion royalty global net sale phase development milestone il achieve result million payment dragonfly include acquire iprd party amend term future milestone require achievement certain criterion specify date bms notifie dragonfly discontinue development il milestone continue consider substantive contingent decision proceed base assessment clinical datum prior specify date january bm notify dragonfly terminate global exclusive license relate dragonfly il termination effective day notification time right revert dragonfly nimbus bms nimbus therapeutic enter settlement resolve legal claim business interest pertain nimbus tyk inhibitor result million income settlement provide bms receive additional amount contingent development regulatory salesbased milestone occurrence certain event approximately change control proceed receive nimbus therapeutic relate tyk inhibitor february takeda acquire ownership nimbus therapeutic tyk inhibitor approximately billion upfront proceed plus contingent sale base milestone aggregate billion bm amend term license arrangement pay party million extinguish future royalty obligation relate mavacamten prior fda approval april result acquire iprd charge note incomeexpense net year end december dollar million interest expense royalty licensing income note royalty income divestiture note equity investment lossesincome net note integration expense note loss debt redemption note divestiture gain note litigation settlement investment income provision restructure note contingent consideration incomeexpense net contingent consideration contingent consideration primarily include fair value adjustment result change trade price contingent value right issue celgene acquisition contractual obligation pay contingent value right terminate january fda approve lisocel jcar december note restructure celgene acquisition plan restructure integration plan implement initiative realize sustainable run rate synergy result cost saving avoidance celgene acquisition celgene acquisition plan result annual synergy billion synergy realize cost product sell marketing sell administrative expense research development expense charge approximately billion expect incur include cash outlay approximately billion cumulative charge approximately billion recognize date include integration planning execution expense employee termination benefit cost accelerate stockbased compensation contract termination cost shutdown cost associate site exit remain charge primarily relate system integration expect incurred employee workforce reduction approximately restructure restructure integration plan initiate realize expect cost synergy result turning point acquisition august myokardia acquisition acquisitionrelate initiative cost save initiative charge approximately million expect incur end acquisitionrelate initiative consist integration planning execution expense employee termination benefit cost cost cumulative charge approximately million recognize action date company transformation restructuring plan announce evolve streamline bmss operating model cumulative charge approximately billion recognize action announcement action plan complete december follow provide charge relate restructuring initiative type cost year end december dollar million celgene acquisition plan restructure company transformation total charge employee termination cost termination cost provision restructure integration expense accelerate depreciation asset impairment shutdown cost net total charge cost product sell marketing sell administrative research development incomeexpense net total charge follow summarize charge spend related restructuring plan activity year end december dollar million liability january provision restructuringa foreign currency translation payment liability december include reduction liability result change estimate million million exclude million accelerate stockbased compensation relate celgene acquisition plan note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision income taxis effective tax rate reconciliation effective tax rate statutory federal income tax rate follow earning income taxis dollar million earningsloss income taxis nonus total statutory rate gilti net foreign derive intangible income deduction foreign tax effect certain operation ireland puerto rico switzerland internal transfer intangible asset federal state foreign contingent tax matter federal researchbase credit charitable contribution inventory contingent value right nondeductible rd charge puerto rico excise tax credit state local taxis net valuation allowance foreign total internal transfer intangible asset streamline legal entity structure subsequent celgene acquisition result tax benefit tax charge adjust defer taxis book revalue tax basis difference relate asset federal state foreign contingent tax matter include million tax benefit respect lapse statute effectively settle contingent tax matter fair value adjustment contingent value right taxable tax deductible nondeductible rd charge primarily result billion myokardia iprd charge puerto rico impose excise tax gross company purchase price good sell bmss manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize bmss provision income taxis excise tax incur december bms amend exist puerto rico decree eliminate excise tax increase puerto rico tax rate effective tax year begin january extend bmss tax grant additional year defer taxis valuation allowance component defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward milestone payment license fee capitalize research expenditure total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability acquire intangible asset goodwill total defer tax liability defer tax liability net recognize deferred income taxis asset noncurrent defer income taxis liabilitie noncurrent total bms indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply bms remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million exist follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal defer tax asset include equity investment fair value adjustment federal net operating loss carryforward change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisitionsdispositionsliquidation net non rate change balance end year certain foreign net operating loss relate valuation allowance utilize eliminate result internal legal entity restructuring income tax payment billion billion billion connection enactment tcja require pay onetime transition tax elect pay period year permit tcja remain amount payable follow million million billion million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follows exclude interest penalty year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense previously disclose bms receive notice propose adjustment irs relate transfer pricing tax issue tax year bms disagree irss position continue work cooperatively irs resolve issue december bm enter irs administrative appeal process resolve matter time final resolution complex matter uncertain material impact bmss financial statement tax position year unrelated matter enter administrative appeal process considered effectively settle reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy japan uk note earningsloss share year end december amount million share datum net earningsloss attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding dilute earningsloss common share basic diluted total number potential share common stock exclude diluted earning share computation antidilutive impact material million note financial instrument fair value measurement financial instrument include cash cash equivalent marketable debt security equity investment account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective nav underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial liability consist acquisition relate contingent consideration success payment relate undeveloped product right result celgene acquisition transfer level year end december financial asset liability measure fair value recur basis summarize december december dollar million level level level level level level cash cash equivalent money market security marketable debt security certificate deposit commercial paper corporate debt security derivative asset equity investment derivative liability contingent consideration liability contingent value right acquisition relate contingent consideration marketable debt security follow table summarize marketable debt security december december gross unrealized gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security total marketable debt security equity investment follow summarize carry equity investment december dollar million equity investment readily determinable fair value equity investment readily determinable fair value limited partnership equity method investment total equity investment follow summarize activity relate equity investment equity investment gainsloss include incomeexpense net dollar million equity investment readily determine fair value net lossgain recognize net lossgain recognize investment sell net unrealized lossgain recognize investment hold equity investment readily determinable fair value upward adjustment impairment downward adjustment equity net incomeloss limited partnership equity method investment cumulative upwards adjustment cumulative impairment downward adjustment base observable price change equity investment readily determinable fair value hold december million million respectively qualify hedge nonqualifye derivative cash flow hedge foreign currency forward purchase local currency option contract hedge certain forecast intercompany inventory purchase sale transaction certain foreign currency transaction fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain loss foreign exchange contract expect reclassify net earning primarily include cost product sell month notional outstanding foreign currency exchange contract primarily attribute euro billion japanese yen billion december bm enter crosscurrency interest rate swap contract hedge exposure foreign currency exchange rate risk associate longterm debt denominate euro contract convert interest payment principal repayment longterm debt dollar euro designate cash flow hedge unrealize gain loss contract report accumulate comprehensive loss reclassify incomeexpense net period hedge debt affect earning notional crosscurrency interest rate swap contract associate long term debt denominate euros million million december treasury lock hedge contract enter total notional value billion hedge future interest rate risk associate anticipate issuance longterm debt fund myokardia acquisition treasury lock contract terminate issuance unsecured senior note million proceed include comprehensive incomeloss net investment hedge nonus dollar borrowing million million december designate net investment hedge hedge euro currency exposure net investment certain foreign affiliate recognize longterm debt effective portion foreign exchange gain remeasurement euro debt include foreign currency translation component accumulate comprehensive loss relate offset long term debt crosscurrency interest rate swap contracts billion december designate hedge currency exposure bmss net investment foreign subsidiary contract fair value change record foreign currency translation component accumulate comprehensive loss relate offset noncurrent asset noncurrent liability notional outstanding crosscurrency interest rate swap contract primarily attribute japanese yen million euro million december fair value hedge fix float interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread gain loss result change fair value underlie debt attributable hedge benchmark interest rate risk record interest expense associate offset carry value debt specific term notional swap intend align debt hedge change fair value swap record interest expense associate offset derivative asset liability consolidate balance sheet result net impact earning underlie swap terminate prior maturity fair value adjustment underlie debt amortize reduction interest expense remain term debt follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract crosscurrency interest rate swap contract foreign exchange contract derivative designate hedge instrument foreign exchange contract total return swap contractsc include current asset noncurrent asset b include current liability noncurrent liability c total return swap contract enter hedge change fair value certain deferred compensation liability follow table summarize financial statement classification gainloss recognize hedging instrument year end december cost incomeexpense cost incomeexpense cost incomeexpense dollar million product sell net product sell net product sell net interest rate swap contract crosscurrency interest rate swap contract foreign exchange contract follow table summarize effect derivative nonderivative instrument designate hedge instrument comprehensive incomeloss year end december dollar million derivative qualify cash flow hedge foreign exchange contract gainloss recognize comprehensive incomeloss reclassify cost product sell crosscurrency interest rate swap contract gainloss recognize comprehensive income reclassify incomeexpense net forward start interest rate swap contract loss reclassify incomeexpense net treasury lock hedge contract gain recognize comprehensive incomeloss derivative qualify net investment hedge crosscurrency interest rate swap contract gainloss recognize comprehensive incomeloss nonderivative qualify net investment hedge non dollar borrowing gainloss recognize comprehensive incomeloss note finance arrangement shortterm debt obligation include december dollar millions nonus shortterm borrowing current portion longterm debt total longterm debt current portion longterm debt include december dollar million principal value float rate note note note note note note note note note note note note note euro note note note note note note note note note note note euro note note note note note note note note note note note note note note note note note note note mature total december dollar million principal value adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost unamortized purchase price adjustment celgene debt total current portion longterm debt longterm debt total fair value longterm debt billion billion december respectively value level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument bms issue aggregate principal billion fix rate unsecured senior note net proceed billion bm issue aggregate principal billion fix rate unsecured senior note proceed net discount defer loan issuance cost billion note rank equally right payment bmss exist future senior unsecured indebtedness redeemable time vary specify redemption price plus accrue unpaid interest bms purchase aggregate principal billion certain debt security billion cash series tender offer redemption connection transaction million loss debt redemption recognize base carry value debt include incomeexpense net bms purchase aggregate principal billion certain debt security approximately billion cash series tender offer redemption connection transaction million loss debt redemption recognize base carry value debt include incomeexpense net repayment note maturity aggregate billion billion billion interest payment billion billion billion aggregate maturity longterm debt year follow billion billion billion billion billion interest payment relate longterm debt year follow billion billion billion billion million credit facility december bms fiveyear billion facility expire january extendable annually year consent lender facility provide customary term condition financial covenant provide backup liquidity bms commercial paper borrowing borrowing outstanding revolve credit facility december available financial guarantee provide form bank overdraft facility standby letter credit performance bond billion december standby letter credit guarantee issue financial institution support obligation include sale product hospital foreign ministry health bond custom duty value add tax note receivable december dollar million trade receivable chargeback cash discount allowance expect credit loss net trade receivables alliance royalty vat receivables nonus receivables sell nonrecourse basis billion billion billion aggregate receivable pharmaceutical wholesaler represent approximately total trade receivables december respectively change allowance expect credit loss chargeback cash discount follow year end december dollar million balance begin year provisiona utilization balance end year include provision expect credit loss million million million note inventory december dollar million finished good work process raw packaging material total inventory inventory noncurrent asset total inventory include fair value adjustment result celgene acquisition approximately million december million december note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment united states international total depreciation expense million million million note lease lease facility office research development storage distribution purpose comprise approximately total lease obligation lease term vary base nature operation market dynamic country lease facility classify operating lease remain lease term year year lease contain specific renewal option period range year year notice renew provide advance lease expiration automatic renewal advance notice require period cover option extend lease include noncancellable lease term exercise option determine reasonably certain certain lease contain termination option provide flexibility terminate lease ahead expiration sufficient advance notice period cover option terminate lease include non cancellable lease term exercise option determine reasonably certain judgment require assess renewal termination option reasonably certain exercise factor consider contractual term compare current market rate leasehold improvement expect significant value cost terminate lease importance facility operation cost determine variable base index rate include measurement real estate lease liability variable cost include real estate taxis insurance utility common area maintenance operating cost implicit rate lease readily determinable incremental borrowing rate apply portfolio approach discount real estate lease liability remain lease obligation comprise vehicle research development facility operate party management direction vehicle lease term vary country term generally year year follow table summarize component lease expense year end december dollar million operating lease cost variable lease cost shortterm lease cost sublease income total operating lease expense operating lease rightofuse asset liability follow december dollar million noncurrent asset current liability noncurrent liability total liability future lease payment noncancellable operating lease december follow dollar million total future lease payment imputed interest total lease liability rightofuse asset obtain exchange new operating lease obligation million cash pay amount include measurement operating lease liability million million million undiscounte lease obligation operating lease commence million december obligation primarily relate research development facility construct lessor expect ready use rightofuse asset impairment charge million incur site vacancy partial sublease fair value rightofuse asset determine income approach incorporate potential future cash flow associate sublease build supplemental balance sheet information relate lease follow december weight average remain lease term year year weight average discount rate note goodwill intangible asset goodwill change carry amount goodwill follow december dollar million begin balance turning point acquisition currency translation adjustment end balance intangible asset intangible asset consist follow december dollar millions estimate gross carry accumulate intangible gross carry accumulate intangible useful life amount amortization asset net amount amortization asset net intangible assetsa license year acquire market product right year capitalize software year iprd total intangible asset include intangible asset recognize turn point acquisition refer note acquisition divestiture license arrangement information relate turning point acquisition amortization expense intangible asset billion billion billion future annual amortization expense intangible asset expect approximately billion billion billion billion billion intangible asset impairment charge million billion billion million iprd impairment charge record research development expense result decision discontinue development investigational compound connection prioritization current pipeline opportunity charge represent writedown million iprd impairment charge investigational compound record research development expense primarily result change clinical timeline expect launch date competitive landscape compound study potential treatment hematologic disease acquire acquisition celgene charge represent partial writedown carry value base estimate fair value determine discount cash flow projection additionally million iprd impairment charge record research development expense follow decision discontinue development investigational compound connection prioritization current pipeline opportunity compound study potential treatment fibrotic disease acquire acquisition celgene charge represent writedown base estimate fair value determine discount cash flow projection inrebic eu regulatory approval milestone million achieve result million increase acquire market product right intangible asset establish applicable defer tax liability impairment charge million recognize cost product sell carry value asset exceed project undiscounted cash flow asset charge equal excess asset carrying value estimate fair value discount cash flow projection million impairment charge record cost product sell result low cash flow projection reflect revise commercial forecast inrebic result impairment asset additionally million impairment charge record research development expense follow decision discontinue orvacel program development inrebic orvacel obtain connection acquisition celgene note supplemental financial information december dollar million income taxis research development contract asset equity investment restrict casha current asset december dollar million equity investment inventory operate lease pension postretirement research development restrict casha noncurrent asset restrict cash consist fund restrict annual company contribution define contribution plan escrow litigation settlement cash restrict withdrawal general use contractually legally restrict december dollar million rebate discount income taxis employee compensation benefit research development dividend interest royalty operating lease current liability december dollar million income taxis pension postretirement operating lease defer income defer compensation noncurrent liability note equity accumulate capital excess common stock treasury stock par value comprehensive retain noncontrolle dollar share million share par value stock loss earning share cost interest balance january net loss comprehensive incomeloss cash dividend declareda share repurchase program stock compensation distribution balance december net earning comprehensive incomeloss cash dividend declareda share repurchase program stock compensation distribution balance december net earning comprehensive incomeloss cash dividend declareda share repurchase program stock compensation distribution balance december cash dividend declare common share bms share repurchase program authorize board director allow repurchase share effect open market privately negotiate transaction compliance rule b exchange act include rule b trading plan share repurchase program obligate repurchase specific number share specific expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method outstanding share repurchase authorization program billion december bm enter accelerated share repurchase asr agreement repurchase aggregate billion company common stock asr agreement fund cash onhand company receive approximately million share common stock year include treasury stock total number share repurchase asr agreement base volumeweighted average price bms common stock term asr transaction discount subject adjustment pursuant term condition asr agreement addition share repurchase program bm repurchase approximately million share common stock billion year end december remain share repurchase capacity share repurchase program billion december component comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial gainslosse amortizationb settlementsb pension postretirement benefit marketable debt security unrealize lossesgain realize gainslossesb marketable debt security foreign currency translation comprehensive incomeloss include cost product sell incomeexpense net refer note financial instrument fair value measurement information b include incomeexpense net accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit marketable debt security foreign currency translationa accumulate comprehensive loss include foreign currency net investment hedge gain million million december december note retirement benefit bms sponsor define benefit pension plan define contribution plan termination indemnity plan certain employee define benefit pension plan net periodic benefit cost define benefit pension plan million million million year end december respectively change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow year end december dollar million benefit obligation begin year service costbenefit earn year interest cost settlement curtailment actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize noncurrent asset current liability noncurrent liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow december dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation follow december discount rate rate compensation increase interest credit rate weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit cost follow year end december discount rate expect longterm return plan asset rate compensation increase interest credit rate yield high quality corporate bond match duration benefit obligation determine discount rate ftse pension discount curve develop discount rate plan expect return plan asset assumption plan base management expectation longterm average rate return achieve underlying investment portfolio factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset actuarial gain loss relate plan benefit obligation primarily result change discount rate postretirement benefit plan comprehensive medical group life benefit provide substantially bm retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory postretirement benefit plan obligation million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material result bristol myers squibb retirement income plan termination million asset hold separate account pension trust fund retiree medical plan payment revert company result excise tax million plan asset fair value pension plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund classify level fair value hierarchy value nav share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company transfer level year end december investment practical expedient consist primarily multiasset fund redeemable daily weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense individual plan investment allocation determine local fiduciary committee composition total asset pension plan december broadly characterize allocation equity security debt security investment contribution estimate future benefit payment company estimate annual contribution future benefit payment expect material saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match define contribution plan expense approximately million million million note employee stock benefit plan shareholder approve stock award incentive plan plan replace previous equity plan plan authorize award form incentive stock option nonqualifie stock option stock appreciation right sar restrict stock restrict stock unit rsus dividend equivalent performance share unit psus market share unit msus stockbased award december plan plan authorize grant equity award plan provide million share authorize grant plus share recapture forfeiture termination award previous equity award plan subject adjustment accordance term plan december million share available award million equity award outstanding stock option rsus msus psus share generally issue treasury stock satisfy bmss obligation plan prior equity award plan plan executive officer employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant sar grantee surrender exercisable right receive common stock andor cash measure excess market price common stock award exercise price bms grant stock option sar year end december option outstanding year generally vest ratably year option grant replacement option hold celgene option holder acquisition celgene provide cliff vest andor long shorter vest period rsus grant executive officer employee subject restriction continuous employment generally vest occur ratably fouryear period grant date subject accelerate vest specify circumstance stock unit right receive stock end specify vest andor deferral period stock unit vote right bms grant nonforfeitable stock unit nonemployee director msus grant executive officer vest condition continuous employment occur ratably year subject accelerate vest specify circumstance number share issue vest msus determine base specified payout factor require market price share specify measurement date grantdate share price market condition award grant prior attainment high payout factor calculate share price measurement date divide share price award date result high percentage payout msus maximum target number msus award grant prior share price payout factor calculate average closing price grant date measurement date trading day immediately precede grant date measurement date psus grant executive officer threeyear performance cycle grant target number stock unit subject adjustment number share issue psus vest determine base achievement specify performance goal performance condition base bmss threeyear total shareholder return relative peer group company market condition range maximum target number psus vest condition continuous employment occur anniversary grant date subject accelerate vest specify circumstance stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate stockbase compensation expense follow year end december dollar million cost product sell marketing sell administrative research development incomeexpense net total stockbase compensation expense income tax benefita income tax benefit exclude excess tax benefit sharebase compensation award vest exercise million million million total stockbase compensation expense year end december include million million million respectively relate celgene postcombination service period expense accelerate vest award relate celgene acquisition material million million respectively follow table summarize stock compensation activity year end december stock option rsus msus psus weighted weight weight weight average number average number average number average number exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million option share rsus fair value msus fair value psus fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december expect vest dollar million restrict stock unit market share unit performance share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share rsus msus psus fair value awards vest rsus replacement awards rsus msus psus total intrinsic value stock option exercise fair value rsus approximate close market price bmss common stock grant date adjust unit eligible accrual dividend equivalent fair value msus estimate grant date monte carlo simulation fair value psus estimate grant date portion relate relative total shareholder return measure monte carlo simulation remain portion base closing market price bmss common stock grant date adjust unit eligible accrual dividend equivalent take account probability satisfy performance condition grant date follow table summarize significant outstanding exercisable option december number option weightedaverage remain weightedaverage aggregate intrinsic value range exercise price million contractual life year exercise price share million outstanding exercisable aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december trading day note legal proceeding contingency bms certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement legal proceeding significant bms believe significant material describe bms believe matter specifically note material adverse effect financial position liquidity bms believe substantial defense matter outcomes bmss legal proceeding contingency inherently unpredictable subject significant uncertainty assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material bmss financial position result operation cash flow particular period furthermore failure successfully enforce bmss patent right likely result substantial decrease respective product revenue generic competition note bms unable assess outcome respective matter able estimate possible loss range loss potentially result matter contingency accrual recognize probable liability incur relate loss reasonably estimate development legal proceeding matter cause change amount previously accrue evaluated reporting period discussion bmss tax contingency note income taxis intellectual property antipd antipdl september danafarber cancer institute danafarber file complaint district court district massachusetts seek correct inventorship relate patent direct method treat cancer pd pdl antibodie specifically danafarber seek add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period district court issue decision rule scientist add inventor patent decision affirm appeal june danafarber file new lawsuit district massachusetts bms seek damage result decision add scientist inventor february bms file motion dismiss complaint august court deny motion dismiss rule danafarber claim damage date district court rule danafarber coinventor patentsare preempt federal patent law january court hold hearing motion file bms request court enter summary judgment bms favor trial schedule march bm file lawsuit district court district delaware astrazeneca pharmaceuticals lp astrazeneca uk ltd collectively az allege az marketing pdl antibody imfinzi infringe certain claim patent nos trial schedule begin april cart october juno sloan kettering institute cancer research ski file complaint patent infringement kite pharma inc kite district court central district california complaint allege kite yescarta product infringe certain claim patent patent concern cart cell technology kite file answer counterclaim assert noninfringement invalidity patent december follow eightday trial jury reject kite defense find kite willfully infringe patent award juno ski reasonable royalty consist million upfront payment run royalty kite sale yescarta expiration patent august january kite renew previous motion judgment matter law move new trial juno file motion seek enhanced damage supplemental damage ongoing royalty prejudgment interest march court deny kite motion entirety april court grant juno motion enter final judgment award juno ski approximately billion royalty interest enhance damage run royalty kite sale yescarta december expiration patent august april kite appeal final judgment court appeal federal circuit court hold oral hearing july august federal circuit panel reverse jury verdict district court decision find patent invalid october juno ski file petition federal circuit panel en banc rehear federal circuit deny january june juno ski file petition writ certiorari supreme court court deny november november juno ski file petition rehear court court deny january ctla january bms file lawsuit district court district delaware astrazeneca pharmaceuticals lp astrazeneca ab collectively az ab allege az ab marketing ctla antibody imjudo infringe certain claim patent nos trial date schedule eliquis europe november january sandoz limited sandoz teva pharmaceutical industries ltd teva limited respectively file lawsuit united kingdom seek revocation uk apixaban composition matter patent relate supplementary protection certificate spc bms subsequently file counterclaim infringement action trial take place february judgment issue april judge find uk apixaban composition matter patent relate spc invalid november bms grant permission court appeal appeal judgment hearing schedule place april similar lawsuit file country europe seek revocation composition matter patent spc relate eliquis trial schedule certain case include norway france early dutch court issue decision deny request bms preliminary injunction prevent atrisk generic launch netherland sandoz prior trial validity dutch composition matter patent spc follow decision uk netherland generic manufacturer begin market generic version eliquis uk netherlands seek market generic version eliquis additional country europe prior expiration patent lead additional infringement invalidity action involve eliquis patent file country europe september trial hold sweden teva challenge validity swedish apixaban composition matter patent relate spc decision issue november confirm validity reject teva claim september bm file request preliminary injunction teva denmark request deny december base find imminent threat launch teva denmark december bms file request preliminary injunction finland teva request grant january prohibit teva offer store sell generic eliquis product finland obtain price reimbursement bms request preliminary injunction enter teva ireland hearing occur february onureg november bms receive notice letter accord notify bms accord file anda contain paragraph iv certification seek approval generic version onureg challenge fda orange bookliste formulation patent expiring response bms file patent infringement action accord district court district delaware trial schedule begin march plavix australia sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex inc subsequently change apotex genrxapotex august genrxapotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court australia grant sanofis injunction subsidiary bms subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidated genrxapotex case august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid bms sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim genrxapotex appeal september court hold claim patent invalid march high court australia deny request bms sanofi hear appeal court decision case remand federal court proceeding relate damage seek genrxapotex bms genrxapotex settle genrxapotex case dismiss australian government intervene matter seek maximum damage million aud million plus interest split bms sanofi allege loss experience pay high price brand plavix period injunction place bms sanofi dispute australian government entitle damage trial conclude september april federal court issue decision dismiss australian government claim damage australian government appeal federal court decision appeal hearing conclude february sprycel january bms receive notice letter xspray pharma ab xspray nanocopoeia llc nanocopoeia handa oncology llc handa respectively notify bm file b nda application contain paragraph iv certification seek approval dasatinib product challenge fda orange bookliste monohydrate form patent expire february bms file patent infringement action xspray district court district new jersey bms file patent infringement action nanocopoeia district court district minnesota november bms file patent infringement action handa district court northern district california trial date schedule action xspray nanocopoeia file motion judgment base pleading hear nanocopoeia motion take place january zeposia october actelion pharmaceuticals ltd actelion pharmaceutical inc actelion file complaint patent infringement united states district court district new jersey bms celgene allege infringement patent patent complaint allege sale zeposia infringe certain claim patent actelion seek damage injunctive relief trial date schedule pricing sale promotional practice litigation plavix state attorney general lawsuit bms certain sanofi entity defendant consumer protection action bring attorney general hawaii new mexico relate label sale andor promotion plavix trial hawaii matter occur february court issue decision sanofi bms impose penalty total million million attribute bms sanofi bms disagree decision appeal oral argument hawaii supreme court occur december bms remain confident merit case likelihood success appeal believe establish reserve warrant matter september party settle new mexico matter product liability litigation bms party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit bms face unfiled claim involve product abilify bms otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose district court northern district florida february bms otsuka enter master settlement agreement establish propose settlement program resolve abilify compulsivity claim file january mdl state court include california new jersey date approximately case comprise approximately plaintiff dismiss base participation settlement program failure comply settlement relate court order remain case mdl litigation resolve inactive case remain new jersey state court case pende canada class action seven individual injury claim case active class action quebec ontario class action certify byetta amylin subsidiary bms lilly codefendant product liability litigation relate byetta litigation involve lawsuit behalf plaintiff include injury plaintiff claim spouse andor beneficiary court majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp april defendant file motion summary judgment base federal preemption motion summary judgment base absence general causation evidence mdl jccp motion grant march april respectively mdl jccp decision final claim mdl jccp dismiss thyroid cancer claim pende court dismiss onglyza bms astrazeneca codefendant product liability litigation relate onglyza plaintiff assert claim include claim wrongful death result heart failure cardiovascular injury allege cause use onglyza february judicial panel multidistrict litigation order federal onglyza case transfer mdl district court eastern district kentucky significant majority claim pende mdl pende coordinated proceed california superior court san francisco jccp september jccp court grant defendant motion exclude plaintiff general causation expert january mdl court likewise grant defendant motion exclude plaintiff expert march jccp court grant summary judgment defendant effectively dismiss claim previously pende california state court plaintiff file appeal defendant file summary judgment motion mdl mdl court grant august plaintiffs mdl move alter amend mdl court order defendant oppose november mdl court deny plaintiff motion alter amend summary judgment order plaintiff file notice appeal december bmss global diabete business divestiture bms sell onglyza astrazeneca february potential liability respect onglyza expect share astrazeneca security litigation celgene security litigation begin march putative class action file celgene certain officer district court district new jersey celgene security class action complaint allege defendant violate federal security law make misstatement andor omission concern trial ge celgene outlook project sale otezla new drug application zeposia court consolidate action appoint lead plaintiff lead counsel coliaison counsel putative class february defendant file motion dismiss plaintiff amend complaint december court deny motion dismiss grant motion dismiss include claim arise allege misstatement ge court give plaintiff leave replead dismiss claim elect dismiss claim dismiss prejudice november court grant class certification respect remain claim april certain schwab management investment company behalf certain schwab fund file individual action district court district new jersey assert largely allegation celgene security class action remain defendant action schwab action july defendant file motion dismiss plaintiff complaint march court grant deny defendant motion dismiss consistent decision celgene security class action california public employees retirement system april calper action dfa investment dimensions group inc behalf certain fund american century mutual fund inc behalf certain fund july respectively dfa action american century action gic private limited september gic action file separate individual action district court district new jersey assert largely allegation celgene security class action schwab individual action remain defendant action october action consolidate pretrial proceeding schwab action court consolidate future direct action raise common question law fact schwab action trial date schedule celgene security litigation contingent value right litigation june action file bms district court southern district new york assert claim allege breach contingent value right agreement cvr agreement enter connection closing bmss acquisition celgene corporation november successor trustee cvr agreement allege bms breach cvr agreement allegedly fail use diligent effort obtain fda approval lisocel breyanzi contractual milestone date avoid billion potential obligation holder contingent value right govern cvr agreement allegedly fail permit inspection record response request successor trustee successor trustee seek damage determine trial relief include interest attorney fee bms dispute successor trustee allegation file motion dismiss july june court deny bmss motion dismiss october allege celgene stockholder file complaint district court southern district new york assert claim behalf putative class celgene stockholder receive cvrs bms merger celgene violation section securities exchange act relate joint proxy statement action later consolidate action file court consolidated complaint file assert claim behalf class cvr acquirer bms merger celgene violation section security act section b securities exchange act complaint allege february joint proxy statement materially false misleading fail disclose bms allegedly intention obtain fda approval lisocel breyanzi applicable milestone date cvr agreement certain statement bms certain bms officer periodic sec filing earning call press release investor presentation december november materially false misleading reason defendant move dismiss complaint november allege purchaser cvrs file complaint supreme court state new york new york county assert claim behalf putative class cvr acquirer violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement bms remove action district court southern district new york plaintiff file motion remand action state court court grant september defendant move stay action pende resolution federal action alternative dismiss complaint november allege celgene stockholder file complaint superior court new jersey union county assert claim behalf separate putative class acquirer cvr acquirer bms common stock violation section securities act complaint allege registration statement file connection propose merger transaction celgene bms materially false misleading fail disclose allegedly bms intention time obtain fda approval lisocel breyanzi contractual milestone date complaint assert claim bms member board director time joint proxy statement certain bms officer sign registration statement celgene chairman chief executive officer bms remove action district court district new jersey file motion transfer action district court southern district new york plaintiff file motion remand action state court court grant september defendant move stay action pende resolution federal action alternative dismiss complaint trial date schedule cvr litigation litigation hiv medication antitrust litigation bms sue manufacturer hiv medication relate lawsuit northern district california initial lawsuit file behalf indirect purchaser allege defendant agreement develop sell fixeddose combination product treatment hiv include atripla evotaz violate antitrust law july court grant defendant motion dismiss include dismiss prejudice plaintiff claim overarch conspiracy plaintiff theory base alleged payment royalty patent expiration claim remain october bms enter settlement agreement indirect purchaser court grant final approval settlement september october purport class action file assert similar claim behalf direct purchaser march court dismiss direct purchaser case limit claim remain direct purchaser case arise later court give plaintiff leave amend complaint plaintiff file amend complaint march march bms enter settlement agreement direct purchaser exclude retailer discuss november court grant final approval settlement september additional nonclass action direct purchaser complaint file number retail pharmacy grocery store chain bms manufacturer hiv medication complaint allegation similar raise federal court case new mexico state court case describe january bms enter agreement settle case file retail pharmacy grocery store chain case dismiss february bms manufacturer hiv medication sue state court new mexico attorney general state new mexico case allege defendant agreement develop sell fixeddose combination product treatment hiv include atripla agreement settle certain patent litigation violate antitrust law state new mexico october bms state new mexico enter agreement settle new mexico case bms case bms dismiss stipulation november december additional nonclassaction indirect purchaser case file northern district california additional nonclassaction indirect purchaser case file california state court naming bms manufacturer defendant complaint allegation similar federal court case february bms reach settlement agreement nonclassaction indirect purchaser plaintiff case dismiss april additional indirect purchaser plaintiff file nonclass suit bms defendant july bms enter settlement agreement resolve seven remain indirect purchaser case accordingly hiv medication antitrust litigation pende bms resolve thalomid revlimid litigation begin november certain putative class action lawsuit file celgene district court district new jersey allege celgene violate antitrust consumer protection unfair competition law allegedly secure exclusive supply contract allege purpose prevent generic manufacturer secure supply thalidomide active pharmaceutical ingredient b allegedly refuse sell sample thalomid revlimid brand drug generic manufacturer allege purpose bioequivalence test necessary anda submit fda approval market generic version product c allegedly bring unjustified patent infringement lawsuit order allegedly delay approval propose generic version thalomid revlimid andor allegedly enter settlement patent infringement lawsuit certain generic manufacturer allegedly anticompetitive effect plaintiff behalf putative class thirdparty payer seek injunctive relief damage lawsuit consolidate master action purpose march celgene reach settlement class plaintiff october court enter final order approve settlement dismiss matter settlement resolve claim certain entity opt settlement march humana inc humana opted settlement file lawsuit celgene district court district new jersey humanas complaint make largely claim allegation settle thalomid revlimid antitrust class action litigation complaint purport assert claim behalf humana subsidiary capacity include direct purchaser indirect purchaser seek thing treble punitive damage injunctive relief attorney fee cost celgene file motion dismiss humanas complaint april court issue order deny celgene motion dismiss order address celgene argument certain humanas claim bar statute limitation court order address celgene ground dismissal instead direct celgene present argument renew motion dismiss follow filing amend complaint humana file amend complaint celgene bm assert claim base additional factual allegation celgene bms file motion dismiss humanas amend complaint fully brief november trial date schedule united healthcare services inc uhs blue cross blue shield association bcbsa bcbsm inc health care service corporation hcsc blue cross blue shield florida inc cigna corporation cigna molina healthcare inc molina msp relate entity msp recovery claim series llc mspa claims llc maomso recovery ii llc series pmpi segregate series maomso recovery ii llc msp recovery claim series llc msp recovery claim prov series llc msp recovery claim caid series llc msp file lawsuit make largely claim allegation settle class action litigation humana optout action certain matter additional claim relate copay assistance thalomid revlimid case pende district court district new jersey celgene bmss motion dismiss humana amend complaint apply optout action optout action proceed describe respect humana opt action trial date schedule molina sue celgene bms san francisco superior court molinas complaint make largely claim allegation settle class action litigation june san francisco superior court dismiss molinas claim molina later reassert district new jersey describe stay remain claim activity expect case disposition new jersey action certain entity opt nowsettle class action file summons relate action philadelphia county court common plea connection allegation humana optout entity action place deferred status pende development optout case november certain direct purchaser file action celgene bms certain generic manufacturer district court district new jersey action make largely claim allegation celgene bms respect revlimid settle class action litigation seek injunctive relief damage sherman antitrust act trial date schedule november certain indirect purchaser file putative class action lawsuit celgene bm generic manufacturer district court district new jersey action allege anticompetitive conduct seek injunctive relief damage connection settlement revlimidrelate patent infringement lawsuit trial date schedule humana file lawsuit celgene pike county circuit court commonwealth kentucky humanas complaint allege celgene engage unlawful offlabel marketing connection sale thalomid revlimid assert claim celgene fraud breach contract negligent misrepresentation unjust enrichment violation new jersey racketeer influence corrupt organization act humana subsequently dismiss claim breach contract voluntarily complaint seek thing treble punitive damage injunctive relief attorney fee cost trial matter begin january celgene file suit humana pharmacy inc hpi humana subsidiary delaware superior court celgene complaint allege hpi breach contractual obligation celgene assign claims humana humana asserting complaint seek damage hpis breach declaratory judgment trial schedule march beigene arbitration matter july celgene logistics srl celgene logistics beigene ltd assignee beigene enter license supply agreement lsa pursuant beigene grant thing exclusive license distribute commercialize revlimid vidaza abraxane china beigene initiate arbitration proceed celgene logistic bms international chamber commerce june assert claim include breach contract lsa october celgene logistic deliver notice beigene terminate lsa respect abraxane final hearing merit hold june party complete postheare briefing closing argument msk contract litigation april memorial sloan kettere cancer center eureka therapeutics inc collectively plaintiff file complaint bms celgene juno collectively defendant june plaintiff file amend complaint plaintiff allege defendant breach license agreement allegedly fail use commercially reasonable effort develop manufacture commercialize certain chimeric antigen receptor product fail pay plaintiff run royalty worldwide sale abecma allegedly owe plaintiff license agreement defendant disagree plaintiff claim file motion dismiss amend complaint july trial date schedule government investigation like pharmaceutical company bms certain subsidiary subject extensive regulation national state local authority country bms operate result bms time time subject governmental regulatory inquiry investigation threaten legal action proceeding possible criminal charge substantial fine andor civil penalty result government regulatory investigation environmental proceeding previously report bms party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity bmss current site waste disposal reprocess facility operate party cercla remediation matter respect cercla remediation matter bm responsible state federal international law bm typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party bms accrue liability probable reasonably estimable bms estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive incomeloss cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion critical audit matter critical audit matter communicate matter arise currentperiod audit financial statement communicate require communicate audit committee relate account disclosure material financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate grosstonet rebate accrual medicaid medicare manage healthcare refer note revenue financial statement critical audit matter description fully disclose note financial statement company reduce gross product sale list price time revenue recognize expect chargeback discount rebate sale allowance product return refer grosstonet gtn adjustment reduction attribute commercial arrangement manage healthcare organization government program mandate reduction list price chargeback cash discount reflect reduction receivables settle issuance credit customer rebate discount adjustment reflect liability settle cash payment certain gtn liability relate medicaid medicare manage healthcare organization rebate program gtn rebate accrual involve use significant assumption judgment calculation significant assumption judgment include consideration legal interpretation applicable law regulation historical claim experience payer channel mix current contract price unbilled claim claim submission time lag inventory level distribution channel give complexity involve determine significant assumption calculate certain gtn rebate accrual auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate gtn rebate accrual include follow evaluate appropriateness consistency company method assumption calculate gtn rebate accrual test effectiveness internal control review company estimation model include underlying assumption key input company process calculate gtn rebate accrual test mathematical accuracy gtn rebate accrual test significant assumption key input calculate gtn rebate accrual evaluate company ability estimate gtn rebate accrual accurately compare actual amount incur gtn rebate accrual historical estimate test overall reasonableness gtn rebate accrual record period end develop expectation comparison actual record balance involve audit professional industry quantitative analytic experience assist perform auditing procedure taxis unrecognize tax benefit liabilitie transfer pricing refer note income taxis financial statement critical audit matter description fully disclose note financial statement company recognize certain income tax benefit associate transaction operate company relate foreign affiliate income tax benefit estimate base transfer pricing agreement thirdparty transfer pricing study company judgment morelikelythannot benefit realize tax benefit ultimately realize company determine judgment accrue unrecognized tax benefit liability amount recognize unrecognized tax benefit liability relate transfer pricing significantly affect subsequent period factor change tax law identification additional relevant fact change company judgment measurement tax benefit ultimate settlement tax authority give complexity associate significant assumption judgment calculate unrecognized tax benefit liability relate transfer pricing auditing estimate involve especially subjective judgment critical audit matter address audit audit procedure relate unrecognized tax benefit liability relate transfer pricing include follow evaluate appropriateness consistency company method assumption identification recognition measurement disclosure unrecognized tax benefit liability test effectiveness internal control review underlie assumption key input company process calculate unrecognized tax benefit liability obtain understand company relate party transaction transfer pricing policy test mathematical accuracy unrecognized tax benefit liability test completeness unrecognized tax benefit liability test reasonableness underlie tax position amount accrue selection unrecognized tax benefit liability review company evaluation relevant fact tax law associate tax position test significant assumption input calculate unrecognized tax benefit liability reference party datum information produce entity understand transfer pricing principle tax law inquire management evaluate company appropriately consider new information significantly change recognition measurement disclosure unrecognized tax benefit liability involve income tax specialist audit professional industry experience assist perform auditing procedure deloitte touche llp morristown new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure define exchange act rule ae de end period cover base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting define exchange act rule af supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form k issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item b information item c disclosure foreign jurisdiction prevent inspection applicable report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp morristown new jersey february iii item director executive officer corporate governance reference proxy statement respect director incorporate reference hereof response information require item b information require item respect executive officer include ia reliance general instruction g instruction item b regulation sk incorporate reference hereof response information require item item executive compensation reference proxy statement respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement respect certain relationship relate transaction incorporate reference hereof response information require item item principal accountant fee service reference proxy statement respect aggregate fee bill principal accountant deloitte touche llp pcaob d incorporate reference hereof response information require item iv item